PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 1A PHASE 1, NON- RANDO MIZED, OPEN -LABEL STUDY TO ASSESS THE 
PHARMACOKINETICS, SAFETY AND TOLERABILIT Y OF PF -07321332
BOOSTED WITH RITONAVIR IN ADULT PARTICIPANTS WITH RENAL 
IMPAIRMENT AND IN HE ALTHY PARTICIPANTS W ITH NORMAL RENAL 
FUNCTION
Study Intervention Number : PF-07321332
Study Intervention Name: N/A
USIND Number: [ADDRESS_532825] Number: N/A
ClinicalTrials.gov ID: [STUDY_ID_REMOVED]
Protocol Number: C4671011
Phase: 1
Brief Title: Renal I mpairment Study  of PF -07321332
This document and accompanying materials contain confidential information belonging to [COMPANY_007]. Except as 
otherwise agreed to in writing, by [CONTACT_422102], you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289] ) or 
use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, [COMPANY_007] 
must be promptly notified.

PF-[ADDRESS_532826] of country  health authorities and IRBs/ECs and an y global protocol administrative 
clarification letter.
Protocol Amendment Summary of Changes Table
Amendment 2 (08- July-2021)
Overall Rationale for the Amendment: This study  is being amended to reflect the changes 
made to the exclusion criteria in response to the FDA feedback. 
Section # and 
NameDescription of Change Brief Rationale
Section 5.2.1. All 
ParticipantsAdded the following bullets to 
“Medical Conditions”
1.Positive test result for SARS -
CoV -2 infection at the time of 
screening or Day  -1.
2.History  of HIV infection, 
hepatitis B, or hepatitis C; positive 
testing at screening for HIV, 
HBsAg, HBcAb, or HCVAb. As an 
exception a positive HBsAb test due 
to Hepatitis B vaccination is 
allowed.Update din response 
to the 
FDA feedback on exclusion 
criteria.
Amendment 1 (25- June -2021)
Overall Rationale for the Amendment: This study  is being amended to reflect the changes 
to the study  design that number of participants to 
be enrolled was increased from “32” to 
“36”. Additionally , classification wasprovided to specify  the time for safety  follow -up and 
laboratory  testing , and eGFR ranges for mild renal impairment . The tabl esfor prohibited and 
precautionary  medications in Appe ndix 8 were updated to provide supplementary details.

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 3Section # and 
NameDescription of Change Brief Rationale
Section 1.1 
Synopsis Added “Day  1” for safety  
assessment ; specif ied28 to [ADDRESS_532827] “last” dose for safety follow -up 
call; update d the number of 
participants to be enrolled from “32” 
to “36”.Updates to reflect the changes 
added to the main text.  
Section 1.3 SoA Specif iedin footnote “c” that 
telephone contact [CONTACT_67582] 28 to 
35days from “the last 
administration of ritonavir” or from 
the time of earl y 
termination/discontinuation;
Modif iedfootnote “h” to state tests 
will be performed “at Screening, 
Day -1, Day  3, and earl y termination 
day”;
Addedthe following text to footnote 
“j”:“Serum creatinine laboratory  
test may  be repeated once to confirm 
results at the discretion of the 
investigator; the last value will be 
used to calculate eGFR.”
Specif iedtime points for COVID -[ADDRESS_532828] on “S1, S2, and Day  -1 
(only  [ADDRESS_532829] needed if S 2 = Day  -1)”.Classification of time window 
for phone call and specified 
lab tests. 
Section 1.3 SoA, 
Pharmacokinetic 
Sampling SchemaPharmacokinetic Sampling Schema 
Table was updated to clarify  the PK 
sampling schema.Updated for consistency  in 
protocol and in alignment 
with PACL  18 May  2021.
Section 4.1 
Overall design  In Table 1, for Cohort 2 the 
estimated eGFR range was updated 
to “60 - <90”; f or Cohort 3, the 
number of participants was updated 
to “8 (up to 12)”. The number of 
participants was updated 
accordingl y to “36” in the following 
text. 
Added “Serum creatinine laboratory  
test may  be repeated once to confirm 
results at the discretion of the Update s made to reflect the 
current design of the study.
To align with SoA footnote j

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 4Section # and 
NameDescription of Change Brief Rationale
investigator; the last value will be 
used to calculate eGFR”.
Section 5.1.3. 
Additional 
Inclusion Criteria 
for Participants 
with I mpaired 
Renal Function 
(Cohort 1 and 
Cohort 2 & Cohort 
4 [If Applicable] 
Only )Modif iedthe eGFR range for mild 
renal impairment to “60 –
<90mL/min”Updates made to reflect the 
current design of the study.
Section 5.2.1 All 
ParticipantsAdded“at investigator discretion” 
for item 2; 
Update d exclusion time window for 
Covid -19 vaccination to “within the 
past 1 week of dosing, or are to be 
vaccinated with these vaccines at 
any time during  confinement”.Updates made to reflect the 
current design of the study.
Section 5.3.1 
Meals and Dietary  
RestrictionsUpdated stud y intervention to 
“PF- 07321332”.
Added “There are no water 
restrictions for dosing with 
ritonavir.”Classification for water and 
dietary  restrictions. 
Section 10.8 
Appendix 8: 
Prohibited and 
Precautionary  
Concomitant 
Medications That 
May Result in DDIIn Table “Prohibited Medications”: 
added drug class: Anti -gout, 
Antipsy chotics.
In Table “Precautionary  
Medications”: added drug class: 
Anesthetic, Antiarrh ythmics, 
Anticancer Agents, Antiemetic, 
Antimy cobacterial, Antiparasitic
Antipsy chotic, Beta Blockers, 
Bronchodilator, Endothelin Receptor 
Antagonist, HIV -[ADDRESS_532830], I ntegrase Inhibitor, 
PDE -5 Inhibitors
Sedative/Hy pnotic, Steroids, 
Stimulant.Provides details on prohibited 
and precautionary  
medications due to potential 
DDI.

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 5Section # and 
NameDescription of Change Brief Rationale
Section 11 
ReferenceAdded reference to investigator’s 
brochu re, and ritonavir USPI .Provides supportive 
information.
Minor editorial changes throughout

PF-[ADDRESS_532831] OF TABLES................................................................................................................. ..11
1. PROTOCOL  SUMMARY...................................................................................................12
1.1. Synopsis .................................................................................................................. 12
1.2. Schema .................................................................................................................... 14
1.3. Schedule of Activities .............................................................................................15
2. INTRODUCTION ...............................................................................................................1 8
2.1. Study R ationale .......................................................................................................18
2.2. Background .............................................................................................................18
2.2.1. Nonclinical Pharmacology..........................................................................192.2.2. Nonclinical Pharmacokinetics and Metabolism .........................................192.2.3. Nonclinical Safety ......................................................................................192.2.4. Clinical Overview.......................................................................................20
2.3. Benefit/Risk Assessment.........................................................................................21
2.3.1. Risk Assessment .........................................................................................222.3.2. Benefit Assessment.....................................................................................242.3.3. Overall Benefit/Risk Conclusion................................................................24
3. OBJECTIVES AND ENDPOINTS .....................................................................................244. STUDY DESIGN................................................................................................................ .24
4.1. Overall Design.........................................................................................................244.2. Scientific Rationale for Study Design.....................................................................29
4.2.1. Choice of Contraception/Barrier Requirements .........................................304.2.2. Collection of Retained Research Samples..................................................30
4.3. Justification for Dose ..............................................................................................304.4. End of Study Definition ..........................................................................................31
5. STUDY POPULATION ......................................................................................................31
5.1. Inclusion Criteria.....................................................................................................31
5.1.1. All Participants ...........................................................................................31
5.1.2. Additional Inclusion Criteria for Healthy Participants with Normal 
Renal Function (Cohort 3 Only) ......................................................................32CCI
PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 75.1.3. Additional I nclusion Criteria for Participants with I mpaired Renal 
Function (Cohort 1 and Cohort 2 & Cohort 4 [I f Applicable] Only )............... 32
5.2. Exclusion Criteria ....................................................................................................33
5.2.1. All 
Participants ...........................................................................................33
5.2.2. Add
itional Exclusion Criteria for Healthy  Participants with Normal 
Renal Function (Cohort 3, Only ) .....................................................................36
5.2.3. Additional Exclusion Criter ia for Participants with I mpaired Renal 
Function (Cohort 1, Cohort 2 and & Cohort 4 [If Applicable] Only )
..............36
5.3. L ifesty le 
Considerations ..........................................................................................37
5.3.1. Meals and Dietary  Restrictions ...................................................................37
5.3.2. Caffeine, Alcohol, and Tobacco .................................................................37
5.3.3. Activity .......................................................................................................38
5.3.4. Contraception ..............................................................................................38
5.4. Screen Failures ........................................................................................................38
6. STUDY INTERVENTIO N(S) AND CONCOMITANT THERAPY .................................39
6.1. Study  Intervention(s) Administered ........................................................................39
6.1.1. Administration ............................................................................................39
6.2. Preparation, Handling, Storage, and Accountability ...............................................39
6.2.1. Preparation and Dispensing ........................................................................40
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................41
6.3.1. Allocation to Study Intervention ................................................................41
6.4. Study  Intervention Compliance ...............................................................................41
6.5. Dose Modification ...................................................................................................41
6.6. Continued Access to Study  Intervention After the End of the Study ......................41
6.7. Treatment of Overdose
............................................................................................41
6.8. Concomitant Therapy ..............................................................................................42
6.8.1. P
articipants with Healthy  Renal Function (Cohort 3 Only ) .......................43
6.8.2. P articipants with Impaired Renal Function (Cohort 1, and Cohorts 2 
& 4 [If Applicable]) .........................................................................................43
6.8.3. Rescue Medicine .........................................................................................43
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................43
7.1. Discontinuation of Study  Intervention ....................................................................43

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 87.2. Participant Discontinuation/Withdrawal From the Study .......................................[ADDRESS_532832] to Follow -Up...................................................................................................45
8. STUDY ASSESSMENTS AND PROCEDURES ...............................................................45
8.1. Efficacy  Assessments ..............................................................................................46
8.2. Saf ety Assessments .................................................................................................46
8.2.1. Phy sical Examinations ................................................................................47
8.2.2. Vital Signs ..................................................................................................47
[IP_ADDRESS]. Respi [INVESTIGATOR_82218] ........................................................................47
[IP_ADDRESS]. Temperature ..............................................................................48
8.2.3. Electrocardiograms
.....................................................................................48
8.2.4. Clinical Safety  Laboratory  Assessments ....................................................49
8.2.5. COVID -
19 Specific Assessments...............................................................49
8.2.6. Pregnancy  Testing ......................................................................................49
8.3. Adverse Events, Serious Adverse Events, and Other Safet y Reporting .................50
8.3.1. Time Period and Frequency  for Collecting AE and SAE Information .......50
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety ...............................................51
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF ...................51
8.3.2. Method of Detecting AEs and SAEs ..........................................................51
8.3.3. Follow -Up of AEs and SAEs ......................................................................51
8.3.4. Regulatory
 Reporting Requirements for SAEs ...........................................52
8.3.5. Environmental Exposure, Exposure During Pregnancy  or 
Breastfeeding, and O ccupational Exposure .....................................................52
[IP_ADDRESS]. Exposure During Pregnancy ......................................................52
[IP_ADDRESS]. Exposure During Breastfeeding ................................................54
[IP_ADDRESS]. Occupational Exposure .............................................................54
8.3.6. Cardiovascular and Death Events ...............................................................55
8.3.7. Disease -Related Events and/or Disease -
Related Outcomes Not 
Qualifying as AEs or SAEs ..............................................................................[ADDRESS_532833]
.............................................................55
[IP_ADDRESS]. Lack of Efficacy ........................................................................55
8.3.9. Medical Device Deficiencies ................................ ................................ ......55

PF-07321332
Protocol C4671011Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 98.3.10. Medication Errors .....................................................................................55
8.4. Pharmacokinetics ....................................................................................................56
8.4.1. Plasma for Analysis of PF-07321332.........................................................568.4.2. Urine for Analysis of PF-07321332 ...........................................................57
8.7. Immunogenicity Assessments .................................................................................58
8.8. Health Economics ...................................................................................................58
9. STATISTICAL CONSIDERATIONS ................................................................................58
9.1. Statistical Hypotheses .............................................................................................589.2. Analysis Sets ...........................................................................................................589.3. Statistical Analyses .................................................................................................59
9.3.1. Other Safety  Analyses ................................................................................60
[IP_ADDRESS]. Pharmacokinetic Analyses ........................................................60
9.4. Interim Analyses .....................................................................................................619.5. Sample Size Determination.....................................................................................62
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..........................................................................................................63
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ...............63
10.1.1. Regulatory and Ethical Considerations ....................................................63
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................63
10.1.2. Financial Disclosure .................................................................................6410.1.3. Informed Consent Process ........................................................................6410.1.4. Data Protection .........................................................................................65
10.1.5. Committees Structure ...............................................................................65CCI
CCI
PF-07321332
Protocol C4671011Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 1010.1.5.1. Data Monitoring Committee ...................................................65
10.1.6. Dissemination of Clinical Study Data ......................................................6510.1.7. Data Qualit y Assurance ............................................................................67
10.1.8. Source Documents....................................................................................6810.1.9. Study and Site Start and Closure ..............................................................6810.1.10. Publication Policy...................................................................................6910.1.11. Sponsor’s Qualified Medical Personnel .................................................70
10.2. Appendix 2: Clinical Laboratory Tests .................................................................7110.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-Up, and Reporting .....................................................................72
10.3.1. Definition of AE .......................................................................................7210.3.2. Definition of an SAE ................................................................................7310.3.3. Recording/Reporting and Follow-Up of AEs and/or SAEs During 
the Active Collection Period............................................................................74
10.3.4. Reporting of SAEs....................................................................................78
10.4. Appendix 4: Contraceptive and Barrier Guidance ................................................80
10.4.1. Male Participant Reproductive Inclusion Criteria ....................................8010.4.2. Female Participant Reproductive Inclusion Criteria.................................8010.4.3. Woman of Childbearing Potential ............................................................8110.4.4. Contraception Methods.............................................................................82
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-Up Assessments .......85
10.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................8710.8. Appendix 8: Prohibited and Precautionary Concomitant Medications That 
May Result in DDI ....................................................................................................89
10.9. Appendix 9: Abbreviations ...................................................................................[ADDRESS_532834] OF TABLES
Table 1. Renal Function Categories by  [CONTACT_238116] ................................ ........... 25
Table 2. Criteria to Establish Stable Renal Function ..............................................29
Table 3. Plasma PK Parameters ..............................................................................61
Table 4. Urine PK Parameters ................................................................................61
Table 5. Protocol -Required Safet y Laboratory  Assessments .................................71

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 121.PROTOCOL SUMMARY 
1.1.Synopsis 
Brief Title: Renal I mpairment Study  of PF -[ADDRESS_532835] of renal impairment on the plasma PK 
of PF -07321332/ritonavir. Findings from this study  will be used to develop dosing 
recommendations so that the dose and/or dosing interval may  be adjusted appropriatel y in the 
presence of renal disease.
Objectives and Endpoints
Objectives Endpoints
Prim ary: Prim ary:
Part 1: To evaluate the effect of mild (if 
applicable) and moderate renal impairment on 
the PKof PF -07321332, following a single 
oral dose administration of PF -07321332 
pharmacokinetically boosted with ritonavir.
Part 2: To evaluate the effect of severe r enal 
impairm ent on the PKof PF -07321332, 
following a single oral dose administration of 
PF-07321332 pharmacokinetically boosted 
with ritonavir.Plasma PF -07321332 PK parameters: C max, 
AUC inf(or AUC lastif AUC infcannot be reliably 
estimated)
Urine PF-07321332 PK parameters: A e, CL r, if 
applicable and as data permit
Secondary: Secondary: 
To evaluate the safety and tolerability of 
PF-07321332 and ritonavir, follow ing a single 
oral dose administration of PF -07321332 
pharmacokinetically boosted with ritonavir, in 
participant s with renal impairment and in 
healthy participant s with normal renal 
function.
To characterize additional PK parameters of 
PF-07321332 follow ing a single oral dose of 
PF-07321332 pharmacokinetically boosted 
with ritonavir by [CONTACT_254488].Safety: treatment -emergent adverse events, 
clinical laboratory tests, vital signs, physical 
examination ,and ECGs.
Plasma PF -07321332 PK parameters: C 12, C24, 
Tmax, AUC last, CL/F, V z/F, and t½, as data permit.
Overall Design
Brief Summary
This is a Phase 1, non- randomized, open- label, 2-part study  to investigate the effect of renal 
impairment on the plasma and urine (if applicable) PK, safet y and tolerability  of a single oral 

PF-[ADDRESS_532836] ed in participants with stable severe renal impairment. A staged approach will be 
followed in the study . Part 1 participants from the moderate renal impairment group 
(Cohort 1) will be recruited first. Enrollment into the mild renal impairment group ( Cohor t 2)
will initiate, if necessary , after preliminary  anal ysis of PK and safet y data from at least 
2participants with moderate renal impairment have been reviewed. The healthy  participants 
(Cohort 3) will be recruited later such that each participant’s age is within ±10 years and 
weight is within ±[ADDRESS_532837] been reviewed.
All participants in both normal and renal impairment groups will provide informed consent 
and undergo Screening evaluations to determine their eligibility . Participants will be selected 
and categorized into normal renal function or renal impairment groups based on their eGFR 
(using the CKD -EPI[INVESTIGATOR_10908]).
Eligible participants will be admitted to the CRU on Day  -1 (at least 12 hours prior to the 
dosing of PF -07321332 on Day 1) and will be confined in the CRU until Day  3. On the 
evening of Day -
1, participants will receive a single 100 mg dose of ritonavir ( -12hour 
relative to PF -07321332 dosing ). On the morning of Day 1, the participants will rec eive a 
single dose of [ADDRESS_532838] -dose for plasma and urine PK 
assessments. 
Safety  assessments will be performed during Screening , on Day  -1 prior to dosing, Day 1, 
and on Day 3. Phy sical examinations, vital sign measurements, and clinical laboratory  tests 
will be conducted ,
and AEs will be monitored to assess safet y. The total participation time 
(eg,CRU confinement time for study  procedures) for each participant in this study  is 
approximately  3nights/ 4days(excluding screening & Follow -Up contact). 
A safet y follow
-up call will be made to participants [ADDRESS_532839] dose of study  intervention.
Number of Participants
Approximately  36participants may be enrolled to study  intervention .
Note: "Enrolled" means a participant's, or his or her legally  
authorized representative’s, 
agreement to participate in a clinical study following completion of the informed consent 
process and screening . A participant will be considered enro lled if the informed consent is 
not withdrawn prior to participating in an y stud y activity  after screening .Potential 

PF-[ADDRESS_532840] Follow-up 
phone call, is approximately  up to 9 weeks.
Data Monitoring Committee or Other Independent Oversight Committee : No
Statistical Methods
ANOVA will be used to compare the natural log transformed AUC inf(or AUC lastif AUC inf 
cannot be reliably  estimated) and Cmaxfor PF-07321332 between normal renal function 
group (Reference) and impaired renal function group s(Test). Estimates of the adjusted mean 
diffe rences (Test- Reference) and corresponding 90% CI will be obtained from the model. 
The adjusted mean differences and 90% CIs for the differences w ill be exponentiated to 
provide estimates of the ratio of the adjusted geometric means (Test/Reference) and 90% CIs 
for the ratios.
1.2.Schema
Not applicable.

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 151.3. S chedule of Activ ities
The SoA table provides an overview of the protocol visits and procedures. Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed in formation on each procedure and assessment required for compliance with the 
protocol. 
The investigator may  sche dule visits (unplanned visits) in addition to those listed i n the SoA table , in order to conduct evaluations or 
assessments required to protect the well -being of the participant .
Visit IdentifieraScreeningbDay -1bDay 1 Day 2 Day 3 Follow -up
Contact[CONTACT_238117]/
Discontinuation 
(DC)Day -28 to Day -2
Days Relative to Day 1
Abbreviations used in this table 
can be found in Appendix 9S1 S2 28-35 Daysc
Informed consent X
Admission to CRU X
Confinement to CRU X → → X
Inclusion/exclusion criteria X X
Medical history X X
DemographydX
Physical examinationeX X X X
Height and weight assessmentfX X X Xg
Safety laboratory tests (blood and 
urine)hX XiX X XgX
eGFR assessmentjX X X Xg
Illegal drug/tobacco/alcohol use X X
Urine alcohol test or alcohol 
breath testX X
Urine or serum pregnancy test 
(WOCBP only)X X X X
Contraception checkkX X X X X X
Serum FSH in post -menopausal 
females amenorrheic ≥12 months 
and under 60 years of ageX
Urine drug screen X X
Single supi[INVESTIGATOR_050] 12 -Lead ECG X X X X

PF-07321332
Protocol C4671011Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 16Visit IdentifieraScreeningbDay -1bDay 1 Day 2 Day 3 Follow-up
Contact[CONTACT_238117]/
Discontinuation 
(DC)Day -28 to Day -2
Days Relative to Day 1
Abbreviations used in this table 
can be found in Appendix 9S1 S2 28-35 Daysc
Vital signs (supi[INVESTIGATOR_30991], 
respi[INVESTIGATOR_697], pulse rate) and temperatureXX X X
HIV, HBsAg, HBcAb, HCVAb 
testinglX
PF-07321332 administration X
Ritonavir administrationmXXX
Plasma PK for PF-07321332 X X X X
Urine PK for PF-07321332 X X X
 
Prior/concomitant treatments X X X →→ XX X
COVID-19 testingoXX X
COVID-19 check temperaturepX X XXX X
COVID-19 questionnaireqX
CRU discharge X
Serious and nonserious adverse 
event monitoringXX X →→ XX X
a. Day relative to start of PF-07321332 dosing (Day 1).
b. Screening will consist of 2 CRU outpatient visits (S1 and S2) between [ADDRESS_532841] administration (Day 1). The second screening visit is only to demonstrate stable renal function with difference between eGFRs at S1 and S2 required to be ≤25% of 
the value obtained at S1. If participant meets all screening criteria at S2 visit, and Day -[ADDRESS_532842] administration of ritonavir or from the time o f early termination/discontinuation. If 
participant demonstrates an increase of >25% in serum creatinine from Day -[ADDRESS_532843] eGFR.
d. Demographics will include race, age, and gender.
e. Complete physical examination at screening (normal renal function; Cohort 3 is at screening only only), Day -1, Day 3, and ea rly termination. Brief physical examination at 
any time point as deemed necessary by [CONTACT_093].
f. Height to be obtained at S1 only, weight to be obtained at S1, S2 and Day -1.g. Only when the participant demonstrates an increase of >25% in serum creatinine from Day -1 to Day of discharge. Only serum cr eatinine and weight information will be 
collected for eGFR assessment. 
h. Safety laboratory assessments include chemistry, hematology, and urinalysis (and microscopy, if needed) and will be performed at Screening, Day -1, Day 3, and early 
termination day. All the assessments must be collected following at least a [ADDRESS_532844]. CCI
PF-07321332
Protocol C4671011Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 17Visit IdentifieraScreeningbDay -1bDay 1 Day 2 Day 3 Follow-up
Contact[CONTACT_238117]/
Discontinuation 
(DC)Day -[ADDRESS_532845] stable renal function defined as ≤25% difference for eGFR values at S2 compared to the value at S1. The average of the 
2 screening eGFR values will be used for participant stratification and group assignment (provided stable renal function is stil l demonstrated). If the renal function stability 
criterion is met but the renal function classification category changes between S1 eGFR and the average of the S1 and S2 eGFRs, the eGFR measurement at Day -1 will 
also be used to determine the appropriate group classification category using an average of all 3 eGFR values, to determine whe ther the participant will be eligible for 
enrollment. The Day -1 eGFR value will be used for PK analysis. The eGFR determination will utilize the 4-variable CKD-EPI [INVESTIGATOR_422083] d. A follow-up eGFR will be 
collected at Day 28 (with window of +3 days to allow for holidays) for any participant who demonstrates an increase of >25% in s erum creatinine from Day -[ADDRESS_532846] may be repeated once to confirm results at the discretion of the investigator; the l ast value will be used to calculate eGFR.
k. Confirmation of appropriate use only.
l. HBsAb will be performed as reflex testing for any participant who is HBsAg negative and HBcAb positive ( Section 10.2 ). HCV RNA will be performed as reflex testing 
for any participant who is HCV Ab positive ( Section 10.2 ).
m. Ritonavir will be administered on Day -1 at -12 hours, Day 1 at 0 hours and 12 hours, and Day 2 at 24 hours, relative to PF-073 [ZIP_CODE] dosing.
 
o. Testing for COVID-19 pathogen by [CONTACT_937]-PCR will be performed prior to being admitted to the clinic for confinement, on S1, S2, a nd Day -1 (only [ADDRESS_532847] needed if S2 = 
Day -1), and if participant develops COVID-[ADDRESS_532848] daily during residence. On days in which vitals are being collected, temperature will only need to be tak en once and documented. 
q. Check exposure to positive case, residence or travel in area of high incidence and COVID-19 related signs and symptoms.
Pharmacokinetic Sampling Schema
Study Day -1 1 2 3
Hours Before/After Dose -12 0a0 . 5 123468 1 0 1 2 2 4 3 6 4 8
PF-07321332 administration X
Ritonavir administration X X XX
PK blood samplingbXXXXXXXXXX X X X
PK urine collectioncX→→→→→→→→→ X→ X
a. Predose PF-07321332 and ritonavir sample collection.
b. Blood samples are to be collected for plasma PK assessment of PF-07321332.c. Urine collections during intervals of ≤24, and >24 and ≤48 hours after PF-07321332 dosing on Day 1. During the designated urine collection intervals ([0-24], and [24-48] 
hours post dose), participants will void ALL urine produced during the designated collection interval, including a forced void at the end of the collection interval, directly 
into pre weighed urine collection container. Urine samples will be analyzed using a validated analytical method in compliance w ith [COMPANY_007] SOPs, only if it is determined by 
[CONTACT_238118] a need to do so, based on review of PF-07321332 plasma PK results.CCI
PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 182.INTRODUCTION
PF-07321332 is a potent and selective inhibitor of the SARS -CoV - 2 3CL protease that is 
currentl y being developed as an oral treatment of COVID -19.Ritonavir is a strong CYP3A4 
inhibitor being used to inhibit the metabolism of PF -07321332 in order to increase plasma 
concentrations of PF- 07321332 to values that are anticip ated to be efficacious.
2.1.Study Rationale 
In vitro and in vivo metabolite profiling suggests that the primary  clearance mechanism for 
PF-07321332 is CYP3A4 mediated oxidation. In a reaction phenot ypi[INVESTIGATOR_422084], CYP3A4 was predicted to be 
the major contributor (f m= 0.99) to the in vitro oxidative metabolism of PF
-07321332. As 
such, in the FIH study , C4671001 , the CYP3A4 inhibitor ritonavir was used to enhance the 
exposure of 
PF-07321332 in order to achieve plasma levels that are anticipated to be 
efficacious. Preliminary  PK data following multiple oral administrations of 
PF-07321332/ritonavir at doses of 75/100 mg, 250/100 mg, and 500/[ADDRESS_532849]  may  play  a significant role in PF -07321332 excretion when 
co-administered with ritonavir , with approximately  32.5% ( PF-07321332/ritonavir 
500/100 mg) to 64.6% 
(PF-07321332/ritonavir 75/100 mg) of the drug excreted unchanged 
in urine across doses at stead y-state, and renal clearance rang ingbetween 3.5 to 4.4 L/h 
across doses. 
PF-07321332/ritonavir is intended for short term (eg, 5day) use, in patients with COVI D -19,
some of whom may  have some degree of impaired renal function. Therefore, the purpose of 
this study  isto characterize the effect of renal impairment on the plasma PK of 
PF-
07321332/ritonavir .Findings from this study  will be used to develop dosing 
recommendations so that the dose and/or dosing interval may  be adjusted appropriatel y in the 
presence of 
renal disease.
2.2.Background 
In December 2019, COVID -[ADDRESS_532850] 
SARS -CoV -23CLpro(Ki = 0.[ZIP_CODE] µM) in a biochemical enzy matic assay . Since the 
3CLprofrom human coronaviruses are structurally similar and share a high degree of 
conservation at the active site of the enzy me, the ability  of PF -07321332 to inhibit the 3CLpro
of other coronaviruses (SARS- CoV -1 and HCoV -229E, MERS, HCoV -OC43, HCoV -HKU1, 
andHCoV -NL63) was also confirmed, indicating a potential for broad spectrum 
anti-coronavirus activity . The coronavirus 3CL  protease is a virall y encoded enzy me that is 
critical to the SARS- CoV -2 replication cy cle, analogous to other obligatory  virally  encode d 
proteases (eg, HIV Protease, HCV Protease).2PF-[ADDRESS_532851]  for clearance of 
PF-07321332 in vitro in liver microsomes (mouse, rat, hamster, rabbit, monkey , and human), 
hepatocy tes (rat, monkey, and human), and in vivo in rat and monkey  after repeat oral dosing 
(Study PF-07321332_09Nov20_084546). In a reaction phenoty pi[INVESTIGATOR_422085], CYP3A4 was predicted to be the 
major contributor (f m= 0.99) to the in vitro oxidative metabolism of PF -07321332. No 
signifi cant CYP3A5 contribution is expected to the metabolism of PF- 07321332 ( Study  
PF-07321332_21Nov20_072016). Urinary  excretion of PF -07321332 following single IV or 
oral doses in rats was approximately  11%, suggesting minor urinary  contributions to the 
overal l elimination of PF -07321332. 
Additional information of the nonclinical PKand metabolism of PF -[ADDRESS_532852] dose administered (1000 mg/kg 
and 600 mg/kg in the rat and monkey  studies, respectivel y).PF-
07321332-related 
 non- adverse, test article - related clinical findings included sporadic occurrence of emesis 
with slight body  weight decreases in monkey s. Monitorable and reversible clinica l pathology  
findings included those possibly suggestive of low -grade inflammation (in rats and monkey s) 
or alterations in the coagulation pathway s (in rats only ) without clinical or microscopic 
correlates. Other  non-adverse  clinical pathology  findings were likely due to the emesis and 
subsequent deh ydration in monkeys. In rats administered 1000 mg/kg/day , lower mean 
absolute and relative heart weights (females) and higher absolute and relative liver weights 
(both sexes) were observed relative to controls. T he lower heart weights had no microscopic 
correlates and were fully reversed at the end of the 2- week recovery  period. Higher liver 
weights correlated with reversible,  non-adverse  microscopic findings of minimal to mild 
severit y in the liver and thyroid gl
and consistent with adaptive changes related to microsomal 
enzy me induction.
PF-07321332 was not  mutagenic or clastogenic in in vitro genetic toxicity  studies and was 
negative in the in vivo rat micronucleus assay  incorporated into the GLP repeat -dose rat 
toxicity  study . 

PF-07321332
Protocol C4671011Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 20The nonclinical studies performed  adequately  support the oral administration of 
PF-07321332 in the clinic for up to 14 days.  
Further details of the nonclinical safety program are provided in the current IB.3
2.2.4. Clinical Overview
Safety, tolerability and pharmacokinetics of PF-07321332 in healthy adult participants is 
currently being explored in an ongoing Phase 1 FIH study (C4671001). Study C4671001 is a 3-part study consisting of SAD (PART-1), MAD (PART-2), and relative bioavailability/food 
effect (PART-3) evaluations. PART-[ADDRESS_532853] of an oral tablet formulation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
PF-07321332
Protocol C4671011Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 21 
 
 
 
 
 
 
 
 
2.3. Benefit/Risk Assessment
PF-07321332/ritonavir is not expected to provide any clinical benefit to healthy participants
or participants with renal impairment in this study. This study is designed primarily tocharacterize the effect of renal impairment on the plasma PK of a single dose of PF-[ADDRESS_532854] renal impairment.
 
 
 
 
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events of PF-07321332 with ritonavir may be found in the IB
3and ritonavir 
USPI4, which are the SRSDs for this study. CCI
CCI
PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 222.3.1. Risk Assessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention(s) :PF-07321332
Emesis Sporadic emesis were observed at ≥100 mg/kg/day of 
PF-07321332 in the 15 -day NHP toxicology study (See IB). 
Based on preliminary data, n o em esis was observed in the 
FIH study C4671001 at single doses of PF -07321332 up to 
1500 m g alone and up to 750 mg administered with ritonavir 
(100 mg at -12h, 0h,12h), and at repeated daily doses 
administered orally for [ADDRESS_532855] in rat neuronal and pulmonary endpoints 
were observed in rat toxicology study at the high dose level 
(1000 mg/kg as single dose ; See IB ). Based on preliminary 
data, n o AEs suggestive of neuronal or pulmonary effects 
were observed in the FIH study C4671001 at single doses of 
PF-07321332 up to 1500 mg alone and up to 750 mg 
administered wit h ritonavir (100 mg at -12h, 0h,12h), and at 
repeated daily doses administered orally for 10days of up to 
500mg PF -[ADDRESS_532856].  
Hem odynamic effects Low level inflammation (increase in fibrinogen) in 15 -day 
NHP toxicology study and changes in platelets, globulin and 
albumin/globulin ratio and coagulation system (increase in 
PT and aPTT) in 14 -day rat toxicology stud y (See IB ). No 
relevant laboratory changes in inflammatory markers have 
been observed in the FIH s tudy C4671001 at single doses of 
PF-07321332 up to 1500 mg alone and up to 750 mg 
administered with ritonavir (100 mg at -12h, 0h,12h), and at 
repeated daily doses administered orally for 10days of up to 
500mg PF -07321332 BID with 100 mg ritonavir BID.Fibrinogen, platelets, PT and aPTT, albumin and 
total proteins will be monitored. 

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 23Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Thyroid function studies In 14 day rat toxicology study at high dose of PF -07321332 
(1000 mg/kg/day) thyroid gland changes observed w ere of 
low severity and without evidence of tissue damage. In the 
FIH study C4671001 , 3participants had TEAEs of elevated 
TSH levels across treatment groups (PF -07321332 or 
placebo w ith ritonavir 100 mg BID) in the MAD part of the 
study. There was no clinical correlation w ith these TSH 
changes and free T4 remained w ithin reference range at all 
times.TSH and free T4 will be evaluated to monitor 
thyroid function
Study Intervention(s): Ritonavir
Gastrointestinal disturbances (including 
diarrhea, nausea, vomiting and 
abdominal pain).Frequently reported adverse reaction in HIV patients at 
600mg BID.Lower dose of 100 mg twice daily is used in this 
study. There will be close observation of AEs. If 
needed, anti -emetics may be provided. 
Neurologic al disturbances (eg, 
paresthesia, including oral paresthesia, 
dysgeusia and dizziness).Frequently reported adverse reaction in HIV patients at 
600mg BID.Lower dose used in this study. There w ill be close 
observation of AEs.  
Rash (most commonly reported as 
erythematous and maculopapular, 
followed by [CONTACT_108135]).Frequently reported adverse reaction in HIV patients at 
600mg BID.Lower dose used in this study. There w ill be close 
observation of AEs and monitoring through 
targeted physical exams. If needed, palliative care 
may be provided. 
Fatigue/Asthenia Frequently reported adverse reaction in HIV patients at 
600mg BID.Lower dose used in this study. There w ill be close 
observation of AEs and monitoring through 
targeted physical exams.
Limited case reports of renal toxicity Although ritonavir therapy is not generally considered 
nephrotoxic, a limited number of cases of acute kidney 
injury secondary to ritonavir have been reported post -
marketing in HIV patients.Lower dose used in this study. The re will be close 
observation of AEs and renal function.

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 242.3.2. Benefit Assessment
PF-07321332 /ritonavir will not provide any  clinical benefit to healthy  participants or 
participants with renal impairment in this study . Any anticipated benefit to participants 
would be 
in terms of contribution to the process of developi[INVESTIGATOR_007] a new therapy  in an area of 
unmet medical need.
2.3.3. Overall Benefit /Risk Conclusion
Taking into account the measures to minimize risk to study participants, the potential risks 
identified in association with PF-07321332/ritonavir are justified b y the anticipated benefits 
that may  be afforded to participants with COVID -19.
3.OBJECTIVES AND ENDPO INTS
Objectives Endpoints
Prim ary: Prim ary:
Part 1: To evaluate the effect of mild (if 
applicable) and moderate renal impairment on 
the PKof PF -07321332, following a single 
oral dose administration of PF-07321332 
pharmacokinetically boosted with ritonavir .
Part 2: To evaluate the effect of severe renal 
impairm ent on the PKof PF -07321332, 
following a single oral dose administration of 
PF-07321332 pharmacokinetically boosted 
with ritonavir.Plasma PF -0732133 2PK parameters: C max, 
AUC inf(or AUC lastif AUC infcannot be reliably 
estimated)
Urine PF-07321332 PK parameters: A e, CL r, if 
applicable and as data permit
Secondary: Secondary: 
To evaluate the safety and tolerability of 
PF-07321332 and ritonavir, follow ing a single 
oral dose administration of PF -07321332 
pharmacokinetically boosted with ritonavir, in 
participant s with renal impairment and in 
healthy participant s with normal renal 
function.
To characterize additional PK parameters of 
PF-07321332 follow ing a single oral dose of 
PF-07321332 pharmacokinetically boosted 
with ritonavir by [CONTACT_254488].Safety: treatment -emergent adverse events, 
clinical laboratory tests, vital signs, physical 
examination and ECGs.
Plasma PF-07321332 PK parameters: C 12, C24, 
Tmax, AUC last, CL/F, V z/F, and t ½, as data permit.
4.STUDY DESIGN
4.1.Overall Design
This is a Phase 1, non- randomized, open- label, [ADDRESS_532857] of renal 
impairment on the plasma and urine (if applicable) PK, safet y and tolerability  of a single oral 
dose of PF -07321332 in combination with the PK boosting agent rit onavir in approximately  

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 2536 participants. Part 1 will be conducted in approximately  24 adult male and female 
participants with stable mild or moderate renal impairment and a control group of 
participants with normal renal function. Part 2 will be conducted in approximately  8 adult 
male and female participants with stable severe renal impairment. A staged approach, as 
outlined in detail below, will be followed in the study .
P
articipants will be selected and categorized into normal renal function or renal impa irment 
groups based on their eGFR as shown in Table 1.
Table 1. Renal Function Categories by [CONTACT_238123] (mL/min) Number of Participants
1 Moderate Renal Impairment ≥30 to <60 8
2 Mild Renal Impairment 60 –<90 8
3 None (Normal) ≥90 8(up to 12)
4 Severe Renal Impairment <30 and not requiring dialysis 8
a.Stages of renal impairment are based on Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical 
Practice Guidelines for Chronic Kidney Disease (CKD) .5
b.Estimate of eGFR based on CKD- EPI [INVESTIGATOR_14420]. The average of the 2 screening eGFR value w ill be used for 
group assignment.
Part 1: Approximately  24 participants will be enrolled in Part 1; approximately  
8participants with moderate renal impairment (Cohort 1), approximately  8 with mild renal 
impairment (Cohort 2), and approximately  8 (up to 12) with normal renal function 
(Cohort 3), to ensure at least 6 evaluable participants in each group. Participants from the 
moderate renal impairment group (Cohort 1) will be recruited first. Enrollment into Cohort 2 
will initiate, if necessary  (see criteria below), after preliminary  anal ysis of PK and safet y data 
from at least [ADDRESS_532858] been reviewed. The healthy  
participants (Cohort 3) will be recruited later such that each participant’s age is within 
±10years and weight is within ±15 kg of the mean of participants within the renal 
impairment groups. An attempt will be made to maintain a similar male/female ratio 
composition between groups . Care will be taken when recruiting the healthy participants 
such tha t the entire group is not of substantially different age or of substantially  different
body  weight than the moderate renall y impaired participants. Approval from the sponsor 
must be obtained before proceeding with dosing healthy  participants with normal re nal 
function.
Participants with stable mild and moderate renal impairment and control participants with 
normal renal function will receive a single [ADDRESS_532859] 
to the primary  PK objective, additional participants can be enrolled at the discretion o f the 
sponsor.

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 26Criteria to enroll Cohort 2:After preliminary evaluation of results from participants with 
moderate renal impairment (Cohort 1), enrollment of participants with mild renal impairment 
(Cohort 2) may  be initiated. Cohort 2 will be conducted i f the estimate of the ratio of 
PF-07321332 AUC inffor the moderate renal impairment group compared to healthy  normals 
is≥1.5.  
Part 2: The decision to conduct Part [ADDRESS_532860] been reviewed. Approximately  
8participants with severe (Cohort 4) renal impairment will be enrolled to ensure at least 
6evaluable participan ts in each group. As in Part 1, renal impairment classification will be 
based on eGFR. Participants will receive a single 100 mg dose of PF- 07321332 administered 
orally  in combination with the PK boosting agent ritonavir administered as a 100 mg dose at 
-12, 0, 12, and 24 hours relative to PF -07321332 dosing .Blood and urine samples will be 
collected for measurement of plasma and urine concentrations of PF- 07321332 as per SoA.
Health y participants from Part 1 will be used as the control group for the severe impairment 
participants. If necessary
, additional participants may  be enrolled into the normal renal 
function group to ensure adequate matching; however the total number will not exceed 12.
The dose of PF -[ADDRESS_532861] to the primary  
PK objective, additional participants can be enrolled at the discretion of the sponsor. 
For both Parts 1 and 2 : All participants in both normal and renal impairment groups will 
provide informed consent and undergo Screening evaluations to determine their eligibility . 
Partici pant screening for participation in this study  will consist of 2 CRU outpatient visits not 
more than 14 days apart (but at least 3 days apart), with the first screening visit occurring 
within [ADDRESS_532862]. An e GFR value for group 
placement (provided stable renal function is still demonstrated) will be obtained by  [CONTACT_422103] 2 screening values (using the CKD -EPI [INVESTIGATOR_10908]). If the renal function 
stability  criterion is met but the renal function classificat ion category  changes between S1 
eGFR and the average of the S1 and S2 eGFRs, the eGFR measurement at Day  -1 will also 
be used to determine the appropriate group classification category  using an average of all 
3 GFR values, to determine whether the partici
pant will be eligible for enrollment. 

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 27Eligible participants will be admitted to the CRU on Day -1 (at least 12 hours prior to the 
dosing of PF -07321332 on Day 1) and will be confined in the CRU until Day  3. If participant 
meets all screening criteria at S2 visit, and Day  -1 visit can be performed immediately , the 
participant may  be admitted to the unit at conclusion of S2 visit. 
On the evening of Day  -1, participants will receive a single 100 mg dose of ritonavir ( - 12hr 
relative to PF -07321332 on Day  1). On the morning of Day  1, the participants will receive a 
[ADDRESS_532863]. Serial blood and urine samples at specified intervals (as per SoA) will 
be collected for [ADDRESS_532864] -dose for plasma and urine PK assessments, prior to discharge 
from the CRU on Day 3. The eGFR value determined on Day  -1 will be used for PK analy sis. 
Safety  assessments (as specified in the 
SoA)will be performed during S1, on Day -1 prior to 
dosing, Day 1, and on Day 3. Onl y serum creatinine will be additionally assessed on S2 for 
eGFR estimation. Physical examinations, vital sign measurements, and clinical laboratory  
tests will be conducted and AEs will be monitored as per SoA to assess safety . The total 
participation time (ie, CRU confinement time for study  procedures) for each participant in 
this study  is approximately  3nights/4 days (excluding screening & Follow -Up contact). 
Participants will have a follow -up phone contact 28-[ADDRESS_532865] -ritonavir 
administration or from the time of early  termination/discontinuation to assess for AEs. If 
participant demonstrates an increase of >25% in SCr from Day  -[ADDRESS_532866] Follow -up phone call, is approximately  up 
to 9 weeks.
All procedures and their timelines follow the SoA.
Calculation of eGFR:
The following CKD -EPI [INVESTIGATOR_422086] (S cr, std denotes serum 
creatinine measured with a standardized assay  for serum creatinine):
If female and SCr is ≤0.7 mg/dL:
eGFR (mL/min/1.73 m2) = 144 × (S Cr, std/0.7) –0.329× 0.993age(× 1.159, if Black)
If female and SCr is >0.7 mg/dL:
eGFR (mL/min/1.73 m2) = 144 × (S Cr, std /0.7) –1.209× 0.993age(× 1.159, if Black)
If male and SCr is ≤0.9 mg/dL:
eGFR (mL/min/1.73 m2) = 141 × (S Cr, std /0.9) –0.411× 0.993age(× 1.159, if Black)

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 28If male and SCr is >0.9 mg/dL:
GFR (mL/min/1.73 m2) = 141 × (S Cr, std /0.9) –1.209× 0.993age(× 1.159, if Black)
Note that the value of eGFR, which is directl y obtained from the laboratory or calculated 
using the equation above, is generall y normalized to an average bod y size of 1.73 m2for 
diagnosis, prognosis and treatment of renal disease. In terms of clearance of renall y filtered 
drugs (including secreted drugs), renal elimination capacity  is related to absolute GFR 
inmL/min. To use the CKD -EPI-derived, BSA -adjusted value of eGFR to obtain absolute 
GFR (mL/ min) for renal disease classification or participant assignment into different renal 
disease groups, this value should be multiplied by  [CONTACT_172619]’s BSA 
(ie,measured BSA/1.73 m2). The BSA of an individual can be calculated by [CONTACT_422104]:
BSA = ( Weight0.425× Height0.725) × 0.007184
In summary , GFR in mL/min calculated as below will be used for renal impairment group 
placement: 
Step 1: Obtain the CKD -EPI-derived eGFR:
Step 2: Convert the CKD -EPI-derived, BSA -adjusted eGFR obtained above to absolute 
GFR (mL/min) for eligibility  assessment using the following equation: 
eGFR (mL/min) = eGFR (mL/min/1.73m2) × participant’s BSA, where BSA is 
calculated as BSA = (Weight0.425× Height0.725) × 0.007184.
CL CRwill also be estimated from a spot serum creatinine measurement using the following 
C-G equation:
CL CR(mL/min) = (140 –age [y ears]) × total body  weight (kg) × (0.85 for females)
72 × serum creatinine (mg/dL)
Note that eGFR calculated by  [CONTACT_91019] -EPI [INVESTIGATOR_422087]. Nevertheless, renal function will be estimated using both C -G 
and CKD -EPI [INVESTIGATOR_422088] 
C-G and CKD -EPI [INVESTIGATOR_422089].
To be enrolled into th e study , participant must demonstrate stable renal function, 
with ≤25% change based upon screening S1 eGFR and screening S2 eGFR (calculated b y the 
CKD -EPI [INVESTIGATOR_10908]). The S2 eGFR assessment should be performed between 3 to 14 day s 

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 29after the S1 eGFR assessm ent. The average of these 2 eGFR values will be used for group 
placement based on the renal function classification category.
If the renal function stability  criterion is met and the renal function classification 
category  remains the same between S1 eGFR and the average of the S1 and 
S2eGFRs, participant will be eligible for enrollment.
If the renal function stability  criterion is not met, participant will be screen failed.
If the renal function stability  criterion is met but the renal function classifica tion 
category  changes between S1 eGFR and the average of the S1 and S2 eGFRs, the 
eGFR measurement at Day - 1 will also be used to determine the appropriate group 
classification category  using an average of all 3 eGFR values, to determine whether 
the partic ipant will be eligible for enrollment. 
In case of screen failure related to eGFR stability  and/or change in the renal function 
classification category , participant may  be re -screened once after a 30- day period, provided 
that the initial screen failure is not due to an Inclusion/Exclusion criterion that results in 
permanent disqualification from enrollment (eg, medical history ).This can be done onl y with 
sponsor’s approval.
Please see Table 2 below regarding demonstration of stable renal function:
Table 2. Criteria to Establish Stable Renal Function
Renal function Measurem ent eGFR (mL/min) Criterion for 
stability
S1 G1 N/A
S2 (Within 3 to 14 days after S1) G2 =|G2-G1|×100/G1a
If ≤25%; stable
If >25%; not stable
a. Parenthesis of |  | represents absolute values.
Serum creatinine laboratory  test may  be repeated once to confirm results at the discretion of 
the investigator; the last value wil lbe used to calculate eGFR.
4.2.Scientific Rationale for Study Design
This study  is a Phase 1, non-randomized, open -label study  of PF -07321332 in participants 
with mild and moderate renal impairment and participants with normal renal impairment, 
matched for age, bod y weight and, to the extent possible, for gender composition (Part 1), 
and in participants with severe renal impairment (Part 2). Details on age and body  weight 
matching criteria are specified in Section 4.1. 
PF-07321332 alone is thought to be primarily  eliminated through a CYP450 mediated 
oxidation with CYP3A4 as the major contributor (f m= 0.99) and renal excretion as 
unchanged a minor component. However, in the presence of the CYP3A4 inhibitor ritonavir, 
preliminary  data suggests renal excretion may  play a significant role in PF -[ADDRESS_532867] on exposure of PF -07321332 (<15% increase in C maxand AUC). 
Therefore, the effect of renal impairment on PF- [ADDRESS_532868]. If 
the study  results demonstr ate that moderate renal impairment does not alter PK to an extent 
that warrants dosage adjustment (See Section 4.1 , Criteria to enroll Cohort 2) , mild renal 
impairment will not be evaluated. If the results do not suppor t such a conclusion, enrollment 
will open to mild renal impairment. The decision to conduct Part 2, in participants with 
severe renal impairment, will also be based on results from moderate renal impairment 
participants from Part 1. More specificall y, if d ata from Part [ADDRESS_532869] over the duration of PF -07321332 exposure. 
PF-07321332 is not extensively  bound to human plasma proteins, with f uof 0.31 observed in 
the in vitro protein binding stud y. Thus, no additional blood samples will be collected in this 
study  for ex vivo protein binding anal ysis. 
4.2.1. Choice of Contraception/Barrier Requirements 
Human reproductive safety  data are limited for PF -07321332, but there is no suspi[INVESTIGATOR_143355] y based on the intende d pharmacology  of the compound. Therefore, the 
use of a highl y effective method of contraception is required (see Appendix 4 ).
4.2.2. Collection of Retained Research Samples
Retained Research Samples will be collected and stored for further anal yses which may , for 
example, provide greater understanding of the study  intervention.
4.3.Justification for Dose
A single oral dose of 100 mg PF -07321332, pharmacokineticall y enhanced with ritonavir
(100 mg at -12, 0, 12, and 24 hours relative to PF - 07321332 ),is planned in this study .This is 
anticipated to be at the lower end of the clinicall y effective dose range , and below the 
anticipated Ph ase2/3 dose of PF -07321332/ritonavir of 300/[ADDRESS_532870] been no deaths or serious adverse events or 
S[LOCATION_003]Rs reported. Based on review of preliminary (unaudited) data, all reported adverse 
events have been of mild intensity . There were no clinically  meaningful findings in vital 
signs, ECG , or potential Hy’s Law cases reported during the stud y. 
Doses may  be modified in Part 2based on emerging safet y, tolerabilit y
,and PK data.
The dose of ritonavir to be used in this study  is [ADDRESS_532871] completed the study  if he/she has completed all parts of 
the study , including the last scheduled procedure s hown in the SoA.
5.STUDY POPULATION
This study  can fulfill its objectives only  if appropriate participant s are enrolled. The 
following eligibility  criteria are designed to select participant s for whom participation in the 
study  is considered appropriate. All relevant medical and nonmedical conditions should be 
taken into consideration when deciding whether a particular participant is suitable for this 
protocol .
Prospective approval of protocol deviatio ns to recruitment and enrollment criteria ,also 
known as protocol waivers or exemptions, is not permitted .
5.1.
Inclusion Criteria
5.1.1. All Participants
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Age and Sex :
1. M ale or female p articipants must be 18 to 75 y ears of age, inclusive, at the time of 
signing the ICD .
Refer to Appendix 4forreproductive criteria for male ( Section 10.4.1) and female 
(Section 10.4.2) participants.
Type of Participant and Disease Characteristics:
2.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, and other study  procedures.

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 32Weight:
3.BMI of 17.5 to 40kg/m2; and a total bod y weight >50 kg (110 lb).
Informed Consent:
4.Capable of giving signed informed consent as described in Appendix 1 ,which 
includes compliance with the requirements and restric tions listed in the I CDand in 
this protocol.
5.1.2. Additional Inclusion Criteria for Healthy P articipants with Normal Renal 
Function (Cohort 3Only )
1.No clinically  relevant abnormalities identified by  a detailed medical history , full 
physical examination, including temperature, BPand pulse rate measurement, 
12-lead ECG and clinical laboratory  tests.
2.Normal renal function (eGFR ≥
90mL/min) at 2 Screenin g visits based on the CKD -
EPI[INVESTIGATOR_10908]. 
3.Demographically  comparable to the group of participants with impaired renal 
function.
Each participant’s bod y weight within ±15kg of the mean body  weight of renal 
impairment group .
Each participant’s age within ±10years of the mean age of the renal impairment 
group .
Attempts will be made to ensure that the male- to-female composition of Cohort 3 
is comparable to that in the renal impairment groups; cohorts cannot be comprised 
entirely  of any  one gender.
Other demogr aphic characteristics, such as race and ethnicity , matched as closely  
as possible to the renal impairment group . 
5.1.3. Additional Inclusion Criteria for P articipants with Impaired Renal Function 
(Cohort 1and Cohort 2 & Cohort 4 [If Applicable] Only )
1.Good general health commensurate with the population with chronic kidney  disease 
(renal impairment). “Health” is defined as no clinically  relevant abnormalities 
identified by  a detailed medical history , full phy sical examination, measurement of 
pulse rate and 1 2-lead ECG as well as clinical laboratory  tests (except serum 
creatinine and eGFR). Hypertension, diabetes mellitus, hy perparathy roidism, 
ischemic heart disease and other common co- morbidities in this population are 
possible exemptions, as long as, in the opi[INVESTIGATOR_871], the participant is 

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 33medically  stable, is on a stable drug regimen, and can abide by  [CONTACT_422105] 5.3.1 .
2.Meet the following eGFR criteria during the screening period based on the CKD -EPI 
[INVESTIGATOR_10908]: 
Mild renal impairment: eGFR between 60 – <90mL/min.
Moderate renal impairment: eGFR ≥30 mL /min and <60 mL/min.
Severe renal impairment: eGFR <30 mL/min, but not requiring hemodial ysis. 
The eGFR values obtained at the 2 screening visits should not be more than 
25% different (see Section 4.1 ) .
3.Any form of renal impairment except acute nephritic syndrome (participants with 
history  of previous nephritic sy ndrome but in r emission can be included).
4.Stable concomitant drug regimen (as defined in Section 6. 8) for the management of 
individual participant’s medical conditions; on a case -
by-case basis , with input from 
the sponsor, participants receiving fluctuating concomitant medication/treatment may  
be considered if the underly ing disease is under control
5.2. Exclusion Criteria
5.2.1. All Participants
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Positive test result for SARS -CoV -2 infection at the time of screening or Day -1.
2.History  of HIV infection, hepatitis B, or hepatitis C; positive testing at screening for 
HIV, HBsAg, HBcAb, or HCVAb. As an exception a positive HBsAb test due to 
Hepatitis B vaccination is allowed.
3.Renal transplant recipi[INVESTIGATOR_840].
4.Urinary  incontinence without catheterization , at investigators discretion .
5.Any condition possibly  affecting drug absorption (eg, prior bariatric surgery , 
gastrectom y, cholecy stectomy , appendec tomy).
NOTE : participants who have undergone cholecy stectomy  and/or 
appendectomy are eligible for this study  so long as the surgery  occurred more 
than 6 months prior to Screening.

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 346.Other medical or psy chiatric condition including history  of pancreatitis, recent 
(within the past y ear) or active suicidal ideation /behavior or laboratory  abnormality  or 
other conditions or situations related to COVID -19 pandemic (eg , Contact [CONTACT_422106], residence, or travel to an area with high incidence) that may  incre
ase 
the risk ofstudy  participation or , in the investigator’s judgment, make the participant 
inappropriate for 
thestudy .
Prior/Concomitant Therapy:
7. Participants who have been vaccinated with COVID- [ADDRESS_532872] 
1week of dosing, or are to be vaccinated with these vaccines at an y time during 
confinement .
8.Use of prescription or nonprescription drugs and dietary  and herbal supplements 
within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention . Limited use of nonprescription medications that are not believed to 
affect participant safet y or the overall results of the study may be permitted on a case 
by [CONTACT_238129].
For participants with renal impairment , stable concomitant medications (including 
herbal supplements) may be given following approval by [CONTACT_422107] (eg, standard therapy  
for underl ying diseases), are not contraindicated with th e IP, and are unlikely  to 
interfere with the PK of the I P. 
9.Current use of an y prohibited concomitant medication(s) or those unwilling/unable to 
use a permitted concomitant medication(s). Refer to Section 6.8 Concomi tant 
Therap y.
Prior/Concurrent Clinical Study Experience:
10.Previous administration with an investigational drug within 30 days (or as determined 
by [CONTACT_19970]) or [ADDRESS_532873] dose of study  intervention
used in this study  (whi chever is longer). 

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 35Diagnostic Assessments:
11.A positive urine drug test , for illicit drugs, at Screening: 
NOTE : repeat urine drug testing is notpermitted in this study .
Renal impairment participants may  be eligible to participate after approval from 
sponsor if their drug screen is positive for a prescribed substance that is not expected 
to interfere with the PK of PF-07321332. 
12.Baseline standard 12- lead ECG thatdemonstrates :
Clinically relevant abnormalities requiring treatment (eg , acute my ocardial 
infarction, serious tachy -or brad y
-arrhythmias) or indicating serious underly ing 
heart disease (eg, prolonged PR interval, cardiomy opathy , underl ying structural 
heart disease, Wolff Parkinson–White sy ndrome ); 
Confirmed QTcF >450 msec for participants with normal renal function and 
>[ADDRESS_532874], if deemed necessary : 
AST or ALT level >2 × ULN ;
Total bilirubin level ≥1.5 ×ULN; participants with a history of Gilbert's 
syndrome may  have direct bilirubin measured and would be eligible for this study  
provided the direct bilirubin level is ≤ULN.
14.In the opi[INVESTIGATOR_22747] (or designee), have an y clinically 
significant laboratory  abnormality  that that could affect interpretation of study  data or 
the participant’s participation in the study . 
15.Screening labo ratory  tests with abnormal results may  be repeated once to confirm 
abnormal results (with the same screening number); the last value will be used to 
determine eligibility .
16.Sites may  be permitted to re -screen participants (with a new screening number) who 
initially  do not meet eligibility  criteria once following agreement with the sponsor.
Other Exclusions:
17.History  of regular alcohol consumption exceeding 7 drinks/week for females or 
14 drinks/week for males (1 drink = 5 ounces [150 mL] of wine or 12 ounces
[360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) or binge drinking and/or any  

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 36other illicit drug use or dependence within 6 months of Screening. Binge drinking is 
defined as a pattern of 5 (male) and 4 (female) or more alcoholic drinks in about 
[ADDRESS_532875], breastfeeding female participants. 
19.Blood donation (excluding plasma donations) of approximately  1pi[INVESTIGATOR_11731] (500 mL) or 
more within 
60days prior to dosing .
20.History  of sensitivity  to heparin or heparin -induced thrombocy topenia , only  if 
heparin is used to flush intravenous cathete rs used during serial blood collections.
21.History  of sensitivity  reactions to ritonavir or any  of the formulation components of 
PF-[ADDRESS_532876] of the 
study , site staff otherwise supervised by  [CONTACT_093], and their respective family
members .
5.2.2. Additional Exclusion Criteria for Healthy Participants with Normal Renal 
Function (Cohort 3, Only)
1.Evidence or history  of clinically  significant hematological, renal, endocrine, 
pulmonary , gastrointestinal, cardiovascular, hepatic, psy chiatric, neurological, or 
allergic disease (including drug allergies, but excluding untreated, as ymptomatic, 
seasonal allergies at the time of dosing).
2.Screening supi[INVESTIGATOR_30991] >1 40mm Hg (s ystolic) or >9 0mm Hg (diastolic), following at 
least [ADDRESS_532877]. If BP is >1 40mm Hg (s ystolic) or >9 0mmHg 
(diastolic), the BP should be repeated 2 more times and the average of the 3 BP 
values should be used to determine the participant’s eligibility .
5.2.3. Additional Exclusion Criteria for Participants with Impaired Renal Function 
(Cohort 1, Cohort 2 and & Cohort 4 [ If Applicable] O nly)
1. P articipants requiring hemodialy sis and/or peritoneal dial ysis
2. P articipants with other clinically  significant disease that may  affect the safety  of the 
participant or that may  affect the PK of PF -07321332 . Participants with any 

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 37significant hepatic, cardiac, or pulmonary  disease or participants who are clinically  
nephrotic. Hypertension, diabetes mellitus, hy perparathy roidism, ischemic heart 
disease, etc. a re not cause for exclusion as long as, in the opi[INVESTIGATOR_871], 
the 
participant is medically  stable and any  drugs that are administered for these 
conditions are not expected to interfere with the PKof PF-07321332. 
3.Screening BP≥180 mm Hg (sy stolic) or ≥110 mm Hg (diastolic), following at least 
5minutes of supi[INVESTIGATOR_198620]. If initial BP is ≥180 mm Hg (systolic) or ≥110 mmHg 
(diastolic), the BP should be repeated 2 more times and the average of the 3 BP 
values should be used to det ermine the participant’s eligibility .
5.3.Lifestyle Considerations
The following guidelines are provided:
5.3.1.
Meals and Dietary Restrictions
Participant s must abstain from all food and drink (except water) at least [ADDRESS_532878] on the other day s provided other restrictions are followed.
Water is permitted until 1 hour prior to PF -07321332 administration. Water may  be 
consumed without restriction beginning 1 hour after dosing. There are no water 
restrictions for dosing with ritonavir. 
Noncaffeinated drinks (except grapefruit or 
grapefruit -related citrus fruit juices—see below) may  be co nsumed with meals and 
the evening snack.
Lunch will be provided approximately  4 hours after dosing.
Dinner will be provided approximately  9to 10 hours after dosing.
An evening snack may  be permitted.
Participants will refrain from consuming red wine, gra pefruit ,or grapefruit -related 
citrus fruits (eg, Seville oranges, pomelos) from [ADDRESS_532879] dose of study  
intervention until collection of the final PK blood sample.
While participants are confined, the irtotal daily  nutritional composition should be 
approximately  55% carbohy drate, 30% fat, and 15% protein. The dail y caloric intake 
per participant should not exceed approximately  3200 kcal.
5.3.2. Caffeine, Alcohol, and Tobacco
Participant s will abstain from caffe ine-containing products for [ADDRESS_532880] 
2hours prior to an y scheduled vital sign and ECG measurements.
Participant s will abstain from alcohol for [ADDRESS_532881] at the discretion of the investigator.
Participant s will abstain from the use of tobacco -or nicotine -containing products for 
24 hours prior to dosing and during confinement in the CRU. 
5.3.3. Activity
Participants will abstain from strenuous exercise (eg, heav y lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each blood collection for clinical 
laboratory  tests. Walking at a normal pace will be permitted;
In order to standardize the c onditions on PK sampling day s, participant s will be 
required to refrain from ly ing down (except when required for BP, respi[INVESTIGATOR_2842], 
pulse rate , and ECG measurements), eating, and drinking beverages other than water 
during the first 4 hours after dosing of PF -07321332 (does not appl y to ritonavir 
dosing) .
5.3.4. Contraception
The investigator or his or her designee, in consultation with the participant , will confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant and his or her partner(s) from the permitted list of contraception methods (see 
Appendix 4 Section 10.4.4 )and will confirm that the participant has been instructed in its 
consistent and correct use. At time points indicated in the schedule of activities ( SoA), the 
investigator or designee will inform the participant of the need to use highly  effective 
contraception consistently and correctl y and document the conversation and the participant ’s 
affirmation in the participant ’s chart ( participant s need to affirm their consistent and correct 
use of at least 1 of the selected methods of contraception) considering that their risk for 
pregnancy  may  have changed since the last visit . In addition, the investigator or designee will 
instruct the participant to call immediately  if the selected contraception method is 
discontinued or if pregnancy is known or suspected in the participant or partner.
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequ ently  enrolled in the study . Screen failure data are collected and remain as 
source and are not reported to the clinical database .
Individuals who do not meet the criteria for participation in this study  (screen failure) may  be 
rescreened if prior reason f or not meeting the eligibility  criteria has been resolved.
Rescreening may  onl
y occur with sponsor approval. In the event that the participation of a 

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 39participant in the study  is delay ed, outdated screening procedures can be repeated.
Rescreened participants should be assigned the same participant number as for the initial 
screening.
6.STUDY INTERVENTION(S) AND CONCOMITANT THERAPY
Study  intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, medical device(s) , or study  procedure(s) intended to be administered to a study  
participant according to the study  protocol.
For the purposes of this protocol, study  intervention refers to PF-07321332 and ritonavir.
6.1.Study Intervention(s) Administered
For this study , the investigation
al product sarePF-07321332 (provided as 100 mg tablets)
and ritonavir (provided as 100mg tablets ).
PF-[ADDRESS_532882] itonavir 100 mg tablets will be supplied by  [CONTACT_422108].
6.1.1. Administration
Investigational products will be administered orally  and according to the conditions 
described in the SoA section and Protocol Section 5.3.1 Meals and Dietary  Restrictions.
On Day -1, 12 hours prior to dosing of PF--07321332, participants will receive a 100 mg 
ritonavir tablet (as 1 ×100 mg) with approximately  [ADDRESS_532883] 10 hours, participant s will receive 100mg 
PF-07321332 (as 1 × 100 mg tablet) at approximately  0800 hours (plus or minus 2 hours)
and 100 mg ritonavir (as 1 × 100 mgtablet). Participants will receive 2 additional doses of 
100mg ritonavir (as 1 × 100 mg tablet ) at 12 and 24 hours after receiving PF -
07321332. 
Investigator site personnel will administer study  intervention with ambient temperature water 
to a total volume of approximately  240 mL. Participant s will swallow the study  intervention
whole, and will not manipulate or chew the study  intervention prior to swallowing. 
In order to standardize the conditions of PK sampling, all participant s will be required to 
refrain from l ying down (except when required for BP, pulse rate , and ECG measurements), 
eating, and drinking beverages other than water during the first [ADDRESS_532884] be stored in a secure, environmentally  controlled, and monitored 
(manual or automated recording) area in accordance with the labeled storage 
conditions with access limited to the inv estigator and authorized site staff. At a 
minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonworking day s must 
indicate the minimum and maximum temperature ssince previousl y documented for 
all site storage locations upon return to business.
3.Any excursions from the study  intervention label storage conditions should be 
reported to [COMPANY_007] upon discovery  along with an y actions taken. The site should 
activel y purs ue options for returning the study  intervention to the storage conditions 
described in the labeling, as soon as possible. Once an excursion is identified, the 
study  intervention must be quarantined and not used until [COMPANY_007] provides permission 
to use the study  intervention. Specific details regarding the definition of an excursion 
and information the site should report for each excursion will be provided to the site 
in the I P manual.
4.Any storage conditions stated in the SRSD will be superseded by  [CONTACT_422109] e 
conditions stated on the label.
5.Study  interventions should be stored in their original containers.
6.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention accountability, reconciliati on, and record 
maintenance (ie, receipt, reconciliation, and final disposition records) , such as the 
IPAL or sponsor -approved equivalent .All study  intervention s will be accounted for 
using a study  intervention accountabilit y form/record.
7.Further guidance and information for the final disposition of unused study  
interventions are provided in the I P manual . All destruction must be adequately  
documented. If destruction is authorized to take place at the investigator site, the 
investigator must ensure that th
e materials are destroy ed in compliance with 
applicable environmental regulations, institutional policy , and any  special instructions 
provided b y [COMPANY_007].
Upon identification of a product complaint, notify the sponsor w ithin 1 business day  of 
discovery  as described in the I P manual.
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the study  intervention ready  for administration or dispensing to the participant by [CONTACT_216479]. Dispensing is defined as the provision of study  intervention , concomitant treatments, 
and accompan ying information by  [CONTACT_22806](s) to a healthcare provider, 
participant in accordance with this protocol. L ocal health authority  regulations or in vestigator 
site guidelines may  use alternative terms for these activities.

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 41PF-07321332 and ritonavir tablets will be prepared at the CRU in the individual dosing 
containers b y 2operators, 1 of whom is an appropriately  qualified and experienced member 
of the study  staff (eg, phy sician, nurse, phy sician’s assistant, nurse practitioner, pharmacy  
assistant/technician, or pharmacist). The tablets will be provided to the participant 
in unit 
dose containers and labeled in accordance with [COMPANY_007] regulations and th e clinical site’s 
labeling requirements. 
6.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Study I ntervention
The investigator’s knowledge of the treatment should not influence the decision to enroll a 
particular participant or affect th e order in which participant s are enrolled.
The investigator will assign participant numbers to the participant s as they  are screened for 
the study . All participants enrolled will receive treatment according to the dose/schedule.
6.4.
Study Intervention Compliance
When participants are dosed at the site, they  will receive study  intervention directly  from the 
investigator or designee, under medical supervision. The date and time of each dose 
administered in the clinic will be recorded in the source documents and recorded in the CRF.
The dose of stud y intervention and study participant identification will be confirmed at the 
time of dosing b y a member of the stud y site staff other than the person administering the 
study  intervention. Study site personnel will exami ne each participant’s mouth to ensure that 
the study  intervention was ingested.
6.5. Dose Modification
Dose modifications for PF -07321332 and ritonavir are not allowed in Part 1.The dose of 
PF-07321332 may  be reduced in Part 2 for participants with severe renal disease if 
considered necessary  by [CONTACT_422110] y.
6.6.Continued Access to Study Intervention 
After the End of the Study
No intervention will be pro vided to study  participants at the end of their study  participation.
6.7.Treatment of Overdose
For this study , any  dose of PF -07321332 greater than 100 mg or ritonavir greater than 
200mg within a 24-hour time period will be considered an overdose.
There is no specific treatment for an overdose .
In the event of an overdose, the investigator should:
1.Contact [CONTACT_22840] 24 hours.

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 422.Closely  monitor the participant for an y AEs/SAEs and laboratory  abnormalities for at 
least 5 half -lives or 28 calendar d ays after the overdose of PF -07321332 or ritonavir 
(whichever is longer).
3.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
4.Overdose is reportable to [COMPANY_007] Safety  only when associated with an SAE.
5.Obtain a blood
sample for PK anal ysis within [ADDRESS_532885] dose of 
study  intervention if requested by  [CONTACT_7195] (determined on a case -by-case 
basis).
6.8.Concomitant Therapy
Use of prescription or nonprescription drugs and dietary  and herbal su
pplements are 
prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention. L imited use of nonprescription medications that are not believed to affect 
participant safety  or the overall results of the study ma y be permitted on a case -by-case basis 
following approval b y the sponsor .Acetaminophen/paracetamol may  be used at doses 
of ≤1 g/day .
Hormonal contraceptives that meet the requirements of this study  are allowed to be used in 
participants who are WOCBP (see Appendix 4).
For participants with renal impairment , stable concomitant medications (including herbal 
supplements) may  be given following 
approval by [CONTACT_422111] (eg, standard therapy  for underly ing 
diseases), are not contraindicated with the IP (see Appendix 8 ), and are unlikely  to interfere 
with the PK of the I P.
As PF -[ADDRESS_532886]. Additionally , ritonavir and PF -07321332 
are inhibit ors of CYP3A4. Therefore, medications highl y dependent on CYP3A4 for 
clearance and for which elevated plasma concentrations may  be associated with serious 
and/or life -threatening events are not permitted during dosing of PF- 07321332/ritonavir. A 
non-exhaus tive list of prohibited and precautionary  medications is provided in Appendix [ADDRESS_532887] dose of study  intervention 
will be documented as concomitant treatments.

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 436.8.1. P articipants with Healthy Renal Function (Cohort 3 Only)
In general , participants will abstain from all concomitant treatments (prescription or over the 
counter) as described in Protocol Section 6.8, except for the treatment of AEs. Of note, the 
following restrictions apply :
Limited use of nonprescription med ications that are not believed to affect participant 
safet y or the overall results of the study may be permitted on a case -by-case basis 
after approval b y the sponsor.
6.8.2. P articipants with Impaired Renal Function (Cohort 1 , and Cohort s 2 & 4 [If 
Applicable])
Participants are permitted to be on stable doses of background medications if they are 
considered necessary  for the welfare of the study  participants (eg, standard therapy  for the 
underly ing disease), are not contraindicated with the investigational produc t, and are unlikely  
to interfere with the PK of the investigational product. Whenever possible , attempts must be 
made to notalter the doses and regimens of the concomitant medications after Day 1 and 
until the end of study  on Day 3.
Approved concomitant medications should be administered to renall y impaired 
participants at least 2 hours prior to dosing or withheld until 4 hours after 
PF-07321332 dosing.
6.8.3. Rescue Medicine 
There is no rescue therapy to reverse the AEs observed with PF-07321332 or ritonavir ; 
standard medical supportive care must be provided to manage the AEs. 
7.DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL
7.1.Discontinuation of Study Intervention
It may  be necessary  for a participant to permanently  discontinue study  intervention .Reasons 
for permanent discontinuation of study  intervention include the following 
AE requiring discontinuation in investigator’s view;
Pregnancy ;
Positive COVI D-[ADDRESS_532888] be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further 
receipt of stud y intervention or also from study  procedures, posttreatment study  follow -up, 
and/or future collection of additional information.
7.2.Participant Discontinuation/ Withdrawal F rom the Study
A participant may  withdraw from the stud y at an y time at his/her own request. Reasons for 
discontinuation from the study  include the following:
Refused further study  procedures ;
Lost to follow -up;
Death ;
Study  terminated by  [CONTACT_3211] ;
At the time of discontinuing from the stud y, if po ssible, an earl y discontinuation visit should 
be conducted
.See the SoA for assessments to be collected at the time of study  
discontinuation and follow- up and for an y further evaluations that need to be completed. 
The early  discontinuation visit applies only  to participants who are enrolled/ randomized and 
then are prematurely  withdrawn from the study .Participants should be questioned regarding 
their reason for withdrawal.
If a participant withdraws from the study , he/she may  request destruction of any  remaining 
samples taken and not tested
,and t he investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the participant withdraws from the study  and also withdraw s consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations should be performed and no 
additional data should be collected. The sponsor may  retain and continue to use any  data 
collected befo re such withdrawal of consent.
7.2.1. Withdrawal of Consent 
Participant s who request to discontinue receipt of study  intervention will remain in the study  
and must continue to be followed for protocol -specified follow -
up procedures. The onl y 
exception to this is when a participant specificall y withdraws consent for any further contact 
[CONTACT_78258]. Participant s should notify  the investigator in writing of the decision to withdraw 
consent from future follow -up, whenever possible. The withdrawal of consent should be 
explained in detail in the medical records b y the investigator, as to whether the withdrawal is 
only from further receipt of study  intervention or also from study  procedur es and/or 
posttreatment study  follow -up, and entered on the appropriate CRF page. In the event that 
vital status (whether the participant is alive or dead) is being measured, publicly  available 

PF-[ADDRESS_532889] be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact [CONTACT_14315] . Counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether the participant wishes to and/or should 
continue in the study ;
Before a parti cipant is deemed lost to follow -up, the investigator or designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact [CONTACT_14316]’s medical record ;
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud y-specific procedures.
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Safety  issues should be discussed with the sponsor immediately  upon occurrence or 
awareness to determine whether the participant should continue or discontinue study  
intervention.
Adherence to the stud
y design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening eva luations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
Participants will be screened within 28 days prior to administration of the study  intervention 
to confirm that they  meet the study  population criteria for the study . If the time between 

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 46screening and dosing exceeds 28 days asa result of unexpected delay s (eg, delay ed drug 
shipment), then participants do not require rescreening if the laboratory  results obtained prior 
to first dose administration meet eligibility  criteria.
A participant who qualified for this protocol but did not enroll from an earlier cohort/group 
may be used in a subsequent cohort/group without rescreening, provided laboratory  results 
obtained prior to the first dose administration meet eligibility  criteria for this study . In 
addition, other clinical assessme nts or specimen collections, eg, banked biospecimens, may  
be used without repeat collection, as appropriate.
Every  effort should be made to ensure that protocol -required tests and procedures are 
completed as described. However, it is anticipated that from time to time there may  be 
circumstances outside the control of the investigator that may  make it unfeasible to perform 
the test. I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the participant. When a protocol -required test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible. The study  team must be informed of these incidents in a timely  manner.
Ifan IV catheter is utilized for blood sample collections, ECGs and vital sign assessments 
(pulse rate andBP) should be collected prior to the insertion of the catheter .
For samples being collecte d and shipped, detailed collection, processing, storage, and 
shipment instructions and contact [CONTACT_19987] .
The total blood sampling volume for individual participant s in this study is approximately  
105mL. The actual collection times of blood sampling may  change. Additional blood 
samples may  be taken for safet y assessments at times specified b y [COMPANY_007], provided the total 
volume taken during the study  does not exceed 550 mL during an y period of 
60consecutive 
days.
To prepare for stud y participation, participant s will be instructed on the information in 
Protocol Section 5.3 Lifesty le Considerations andSection 6.8 Concomitant Therap y.
8.1.Efficacy Assessments
Not applicable.
8.2.Safety Assessments
Planned time points for all safety  assessments are provided in the SoA .Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  issues.

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 478.2.1. Physical Examinations
A complete physical examination will include , at a minimum, head, ears, eyes, nose, mouth, 
skin, heart and lung examinations, ly mph nodes, and gastrointestinal, musculoskeletal, and 
neurological s ystems. 
A brief physical examination will include, at a minimum, assessments of general appearance, 
the respi[INVESTIGATOR_2866] s ystems, and participant -reported s ymptoms.
Physical examinations may  be conducted by  a ph ysician, trained ph ysician's assistant, or 
nurse practitioner as acceptable according to local regulation. 
Height and weight will also be measured and recorded as per the SoA. For measuring weight, 
a scale with appropriate range and resolution is used and must be placed on a stable, flat 
surface. Participant s must remove shoes, bulky  layers of clothing, and j ackets so that only  
light clothing remains. They  must also remove the contents of their pockets and remain still 
during measurement of weight. 
Physical examination findings collected during the study  will be considered source data and 
will not be required to be reported, unless otherwise noted. Any  untoward phy sical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE ( Appendix 3 ) must be reported accord ing to the processes in 
Sections 8.3.1 to Section 8.3.3.
8.2.2. Vital Signs
Supi[INVESTIGATOR_78235] ’s arm supported at the level of the heart, and
recorded to the nearest mm Hg after approximately [ADDRESS_532890]. The same arm 
(preferabl y the dominant arm) will be used throughout the study
. Participant s should be 
instructed not to speak during measurements. 
The same properl y sized and calibrated BP cuff will be used to measure BP each time. The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 
done manuall y, pulse rate will be measured in the brachial/radial artery  for at least 
30seconds. When the timing of t hese measurements coincides with a blood collection, BP 
and pulse rate should be obtained prior to the nominal time of the blood collection.
Additional collection times, or changes to collection times, of BP and pulse rate will be 
permitted, as necessary ,to ensure appropriate collection of safety  data.
[IP_ADDRESS]. Respi[INVESTIGATOR_422090]  5minutes of rest in a supi[INVESTIGATOR_422091] [ADDRESS_532891] and before BP measurement.

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Temperature
Temperature will be measured orall y other bod y locations, eg ty mpanic, are acceptable 
provided the same me thod is used and documented throughout the study ). No eating, 
drinking, or smoking is allowed for [ADDRESS_532892] 12-l ead ECGs utilizing limb leads (with a 10 second rh ythm strip) should be 
collected at times specified in the SoA section of this protocol using an ECG machine that 
automatically  calculates the heart rate and measures PR, QT, and QTc intervals and QRS 
complex .Alternative lead placement methodology  using torso leads (eg ,Mason- Likar) 
should not be used given the potential risk of discrepancies with ECGs acquired using 
standard limb lead placement. All scheduled ECGs should be performed after the participant
has rested quietl y for at least 5minutes in a supi[INVESTIGATOR_2547]. 
To ensure safet y of the participant s, a qualified individual at the investigator site will make 
comparisons to baseline measurements. Additional ECG monitoring will occur if a) a 
postdose QTc Finterval is increased b y ≥30msecfrom the baseline andis >450 msecfor 
participants with normal renal function and >470 msec for participants with impaired renal 
function
; or b) an absolute QT value is ≥[ADDRESS_532893] hourl y until 
QTc value s from 2 successive ECGs fall below the threshold value that triggered the repeat 
measurement.
If a) a postdose QTc Finterval remains ≥30msecfrom the baseline andis >450 msecfor 
participants with normal renal function and >470 msec for participants wit h impaired renal 
function
; or b) an absolute QT value is ≥500 msecfor an y scheduled ECG for greater than 
4 hours (or sooner, at the discretion of the investigator); or c) QTcFintervals get 
progressivel y longer, the participant should undergo continuous E CG monitoring. 
Acardiologist should be consulted if QTc F intervals do not return to less than the criteri a
listed above after 8 hours of monitoring (or sooner, at the discretion of the investigator).
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads beplaced in the 
same positions each time in order to achieve precise ECG recordings. If a machine -read QTc 
value is prolonged, as defined above, repeat measurements may  not be necessary  if a 
qualified medical provider’s interpretation determines that the QTcF values are in the 
acceptable range.
ECG values of potential clinical concern arelisted in Appen dix7.

PF-[ADDRESS_532894] any  
clinically  relevant changes occurring during the study in the AE section of the CRF.
Clinically  significant abnormal laboratory  findings are those which are not associ ated with 
the underl ying disease, unless judged by  [CONTACT_78259]'s condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within [ADDRESS_532895] dose of study  intervention 
should be repeated until the values return to normal or baseline or are no longer considered 
clinically  significant b y the investigator or medical monitor.
If such values do not return to normal/bas eline within a period of time judged reasonable by  
[CONTACT_093], the etiology  should be identified and the sponsor notified.
See Appendix 6for suggested actions and follow -
up assessments in the event of potential 
drug-induced liver injury.
If laboratory  values from non- protocol -specified laboratory  assessments performed at the 
institution’s local laboratory  require a change in participant management or are considered 
clinically  significant b y the investigator (eg, SAE or AE or dose modification), then the 
results must be recorded in the CRF.
Participant s may  undergo random urine drug testing at the discretion of the investigator.
Drug testing conducted prior to dosing must be negative for participant s to receive study 
intervention . 
8.2.5. COVID -[ADDRESS_532896] 
25mIU/mL. Pregnancy  tests will be performed in WOCBP at the times listed in the SoA.
Following a negative pregnancy  test result at screening, appropriate contraception must be 
commenced and a second negative pregnancy test result will be required at the baseline visit 
prior the participant ’sreceiving the study  intervention . Pregnancy  tests will also be done 

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 50whenever 1 menstrual cycle is missed during the active treatment period (or when potential 
pregnancy  is otherwise suspected) and at the end of the study . Pregnancy  tests may  also be 
repeated if requested b y IRBs/ECs or if required by [CONTACT_427]. If a urine test cannot be 
confirmed as negative (eg, an ambiguous result), a serum pregnancy  test is required. In such 
cases, the participant must be excluded if the serum pregnancy  result is positive .
8.3.Adverse Events ,Serious Adverse Events , and Other Safety Reporting
The definitions of an AE and an SAE can be found in Appendix 3.
AEs may  arise from s ymptoms or other complaints reported to the investigator by  [CONTACT_2416] (or, when appropriate, b y a caregiver, surrogate, or the participant's legall y 
authorized representative), or they  may  arise from clinical findings of the 
investigator or 
other healthcare providers (clinical signs, test results, etc.).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pur sue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
thestudy  intervention (see Section 7.1). 
During the active collection period as described in Section
8.3.1, e ach participant will be 
questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain specific follow -
up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant ’s participation in the study  (ie, before undergoing 
any study -related procedure and/or receiving study  intervention ), through and including a 
minimum of [ADDRESS_532897] SAE Report Form.
Investigators are not obligated to activel y seek information on AEsor SAE safter the 
participant has concluded study  participation . However, if the investigator learns of an y SAE, 
including a death, at an y time after a participant has completed the study , and he/she 
consi ders the event to be reasonabl y related to the study  intervention, the investigator must 
promptly  report the SAE to [COMPANY_007] using the CT SAE Report Form.
[IP_ADDRESS].
Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.3.[ADDRESS_532898] SAE Report Form immediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any  updated SAE data to the sponsor within 
24 hours of it being available.
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.3.[ADDRESS_532899] to the CRF 
requirements as described in Section 5.4 .
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE sand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurre nces.
8.3.3. Follow -
Up of AEs and SAEs
After the initial AE or SAE report, the investigator is required to proactively  follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 

PF-[ADDRESS_532900] the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulato ry authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs, and investigators.
Investigator safety  reports must be prepared for S[LOCATION_003]R saccording to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives S[LOCATION_003]Rs or other specific safet y information (eg, summary  or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study and will notify  the IRB/EC, if appropriate according to local requirements.
8.3.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, a nd 
Occupational Exposure
Environmental exposure, occurs when a person not enrolled in the study  as a participant 
receives unplanned direct contact [CONTACT_216480]. Such exposure 
may or may  not lead to the occurrence of an AE or S AE. Persons at risk for environmental 
exposure include healthcare providers, famil y members, and others who may be exposed. An 
environmental exposure may  include exposure during pregnancy , exposure during 
breastfeeding, and occupational exposure.
Any such exposure to the study  intervention under study  are reportable to [COMPANY_007] Safet y 
within 24 hours of investigator awareness.
[IP_ADDRESS]. Exposure During Pregnancy
An EDP occurs if:
A female participant is found to be pregnant while receiving or after discontinuing 
study intervention .
A male participant who is receiving or has discontinued study  intervention exposes a 
female partner prior to or around the time of conception .

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 53A female is found to be pregnant while being exposed or having been exposed to 
study  intervention due to environmental exposure. Below are examples of 
environmental EDP :
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by  [CONTACT_78262] .
A male famil y member or healt hcare provider who has been exposed to the study  
intervention by  [CONTACT_78263] .
The investigator must report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irresp
ective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery  (see below for information related to 
termination of pregnancy). 
If EDP occurs in a participant or a participant’s partner, the invest igator must report 
this information to [COMPANY_007] Safety on the CT SAE Report Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Details of the 
pregnancy  will be collected after the start of study  intervention and until [ADDRESS_532901] dose.
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to [COMPANY_007] Safety  using the CT SAE Report Form and EDP Supplemental 
Form. Since the exposure information does not pertain to the participant en rolled in 
the study , the information is not recorded on a CRF; however, a copy  of the 
completed CT SAE Report Form is maintained in the investigator site file.
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all ED P reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] Safet y of the outcome as a 
follow -up to the initial EDP S upplemental Form. In the case of a live birth, the st ructural 
integrit y of the neonate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by [CONTACT_422112] (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
Abnormal pregnancy  outcomes are considered SAEs. If the outcome of the pregnancy  meets 
the criteria for an SAE (ie, ectopic preg nancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y in a live -born bab y, a terminated fetus, 
anintrauterine fetal demise, or a neonatal death), the investigator should follow the 
procedures for reporting SAEs. Add itional information about pregnancy  outcomes that are 
reported to [COMPANY_007] Safet y as SAEs follows: 
Spontaneous abortion includ ingmiscarriage and missed abortion;

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 54Neonatal deaths that occur within [ADDRESS_532902] 
to causa lity, as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the study  intervention. 
Additional information regarding the EDP may  be reques ted by  [CONTACT_456]. Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s). In the case of paternal exposure, the 
investigator will provide the participant with the Pr egnant Partner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
[IP_ADDRESS]. Exposure During Breastfeeding
An exposure during breastfeeding occurs if: 
A female participant is found to be breastfeeding while receiving or after 
discontinuing study  intervention .
A female is found to be breastfeeding while being exposed or having been exposed to 
study intervention (ie, environmental exposure). An example of environmental 
exposure during breastfeeding is a female family  member or healthcare provider who 
reports that she is breastfeeding after having been exposed to the study  intervention 
by [CONTACT_78262] .
The investigator must report exposure during breastfeeding to [COMPANY_007] Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred. The 
information must be reported using the CT SAE Report Form. When exposure during 
breastfeeding occurs in the setting of environmental exposure, the exposure information does 
not pertain to the participant enrolled in the stud
y,so the information is not recorded on a 
CRF. However, a cop y of the completed CT SAE Report Form is maintained in the 
investigator site file.
An exposure during breastfeeding report is not created when a [COMPANY_007] drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use. However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding.
[IP_ADDRESS]. Occupational Exposure
The investigator must report any instance of occupational exposure to [COMPANY_007] Safet y within 
24
hours of the investigator’s awarene ss using the CT SAE Report Form regardless of 
whether there is an associated SAE. Since the information about the occupational exposure 
does not pertain to a participant enrolled in the study , the information is not recorded on a 
CRF; however, a cop y of th e completed CT SAE Report Form must be maintained in the 
investigator site file .

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 558.3.6. Cardiovascular and Death Events
Not applicable.
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable.
8.3.8. Adverse Events of Special Interest
Not applicable.
[IP_ADDRESS]. Lack of Efficacy
This section is not applicable because efficacy  is not expected in the study  population.
8.3.9. Medical Device Deficiencies
Not applicable.
8.3.10. Medication Errors
Medication errors may  result from the administration or consump tion of the study  
intervention by [CONTACT_19995] , or at the wrong time, or at the wrong dosage strength.
Exposures to the study  intervention under stud y may occur in clinical trial settings, such as 
medication errors.
Safety Event Recorded on the C RF Reported on the CT SAE Report 
Form to [COMPANY_007] Safety Within 
24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the study  intervention ;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant .
Such medication errors occurring to a stud
y participant are to be captured on the medicati on 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours .

PF-07321332
Protocol C4671011Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 56Whether or not the medication error is accompanied by [CONTACT_1149], as determined by [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if applicable, any associated AE(s), serious and nonserious, are recorded on the AE page of the CRF.
Medication errors should be reported to [COMPANY_007] Safety within [ADDRESS_532903] SAE Report 
Form only when associated with an SAE.
8.4. Pharmacokinetics 
8.4.1. Plasma for Analysis of PF-07321332 Blood samples of approximately 4 mL, to provide a minimum of 1.5 mL, will be collected 
for measurement of plasma concentrations of PF-07321332 as specified in the SoA.
Instructions for the collection and handling of biological samples will be provided in the laboratory manual or by [CONTACT_456]. The actual date and time (24-hour clock time) of each sample will be recorded.
The actual times may change, but the number of samples will remain the same. All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing. Collection of samples up to and including 10 hours after dose administration that are obtained within 10% of the nominal time relative to dosing (eg, within 6 minutes of a 60-minute sample) will not be captured as a protocol deviation, as long as the exact time of the collection is noted on the source document and the data collection tool (eg, CRF/DCT). Collection of samples more than 10 hours after dose administration that are obtained ≤[ADDRESS_532904] time of the collection is noted on the source document and the data collection tool (eg, CRF/DCT). This protocol deviation window does not apply to samples to be collected more than 10 hours after dose administration at outpatient/follow-up visits with visit windows.
Samples will be used to evaluate the PK of PF-07321332. Each plasma sample will be 
divided into 2 aliquots. Samples collected for analyses of PF-07321332 plasma concentration may also be used to evaluate safety or efficacy aspects related to concerns arising during or after the study, for metabolite identification and/or evaluation of the bioanalytical method,  
 
Samples may be used to evaluate the PK of ritonavir.
Samples collected for measurement of plasma concentrations of PF-[ADDRESS_532905] be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity. Any deviations from the PK sample handling procedure (eg, sample collection and processing steps, interim storage or shippi[INVESTIGATOR_19944]), including any actions taken, must be documented and reported to the sponsor.On a case-by-case basis, the sponsor may make a determination as to whether sample integrity has been compromised.
8.4.2. Urine for Analysis of PF-07321332
Urine will be collected at the intervals outlined in the SoA. Each participant will empty 
his/her bladder just prior to dosing. During the subsequent designated urine collection intervals ([0-24], and [24-48] hours post dose), participants will void ALL urine produced during the designated collection interval, including a forced void at the end of the collection interval, directly into pre-weighed urine collection container. Each collection interval should have its own collection container(s). During the entire collection interval, the container(s) should be stored at 4°C. At the end of each urine collection interval, all urine collected will be thoroughly mixed, total weight of urine will be determined first (weigh the empty container first and then weigh the container at the end of the collection) and then the volume of urine will be calculated by [CONTACT_238134] = 1 and recorded on the CRF. A urine aliquot of 4 mL will be withdrawn for measurement of drug concentrations.
Additional details for collection, processing and storage of urine for analysis of PF-07321332
will be added to the laboratory manual and provided to the investigator site prior to the start of the study.
Urine samples will be analyzed for PF-07321332 using a validated analytical method in 
compliance with [COMPANY_007] SOPs, if it is determined by [CONTACT_238118] a need to do so, based on review of plasma PK results for PF-07321332. Specifically if the estimate of the ratio of PF-07321332 AUC
inffor the moderate renal impairment group compared to healthy 
normals is <1.5, urine samples will be analyzed.  
Urine samples may be used to evaluate the PK of ritonavir or metabolite identification and/or 
evaluation of the bioanalytical method, 
 
 CCI
CCI
PF-07321332
Protocol C4671011Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 58 
 
 
 
 
8.7. Immunogenicity Assessments
Immunogenicity assessments are not included in this study.
8.8. Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in this study.
9. STATISTICAL CONSIDERATIONS
Detailed methodology for summary and statistical analyses of the data collected in this study 
is outlined here and further detailed in a SAP, which will be maintained by [CONTACT_456]. The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.
9.1. Statistical Hypotheses
No statistical hypothesis will be tested in this study.
9.2. Analysis Sets
For purposes of analysis, the following analysis sets are defined:
Participant Analysis 
SetDescription
PK Concentration The PK concentration population is defined as all participants 
assigned to investigational product and treated who have at least [ADDRESS_532906] they actually  
received .
9.3. Statistical Analyses
The SAP will be developed and finalized before any anal yses are pe rformed and will 
describe the anal yses and procedures for accounting for missing, unused, and spurious data.
This section is a summary of the planned statistical analy ses of the primary  and secondary  
endpoints.
ANOVA will be used to compare the natural log transformed AUC inf(or AUC lastif AUC inf
cannot be reliably  estimated) and Cmaxfor PF-07321332 between normal renal function group 
(Reference) and each impaired renal function group separately as applicable (Test). Estimat es 
of the adjusted mean differences (Test-Reference) and corresponding 90% CIs will be
obtained from the model. The adjusted mean differences and 90% CIs for the differences w ill 
beexponentiated to provide estimates of the ratio of the adjusted geometric means 
(Test/Reference) and 90% CIs for the ratios. If substantial differences in demographic 
characteristics between healthy  and impaired participant sare observed, weight and age may  
be explored as covariates.
Box and whisker plots for individual participant parameters ( AUC infand Cmax) will be
constructed b y renal function group and overlaid with geometric means.
For summary  statistics and median/mean plots by [CONTACT_31065], the nominal PK sampling 
time will be used. For individual participant plots by  [CONTACT_5586], the actual PK sampling time will 
beused.
Linear regression will be used to anal yze the potential relationship between appropriate PK
parameters (CL/F or CL r, and V z/F) and renal function (eGFR). Estimates of the slope and, 
intercept, together with their precision (90% CI), and the coefficient of determination will be 
obtained from the model.
Plots of PK parameters (CL /F or CL r, and V z/F) versus renal function (eGFR) will be 
constructed. A regression line and 90% confidence region for the PK parameters and eGFR 
will be included if appropriate. Vertical lines for the renal function group cut -off values will 
also be presented on the plots. Different s ymbols will be used to identify  participant s from 
different renal function groups.

PF-07321332
Protocol C4671011Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 609.3.1. Other Safety Analyses
All safety analyses will be performed on the safety population.
AEs, ECGs, BP, pulse rate, and safety laboratory data will be reviewed and summarized on 
an ongoing basis during the study to evaluate the safety of participants. Any clinical laboratory, ECG, BP, and pulse rate abnormalities of potential clinical concern will be described. Safety data will be presented in tabular and/or graphical format and summarized descriptively, where appropriate.
Medical history and physical examination and neurological examination information, as 
applicable, collected during the course of the study will be considered source data and will not be required to be reported, unless otherwise noted. However, any untoward findings identified on physical and/or neurological examinations conducted during the active collection period will be captured as AEs, if those findings meet the definition of an AE.Data collected at screening that are used for inclusion/exclusion criteria, such as laboratory data, ECGs, and vital signs, will be considered source data, and will not be required to be reported, unless otherwise noted. Demographic data collected at screening will be reported.
 
[IP_ADDRESS]. Pharmacokinetic Analyses
[IP_ADDRESS].1. Analysis PopulationThe PK concentration population will be defined as all participants treated in whom at least 
[ADDRESS_532907].
[IP_ADDRESS].2. Derivation of Pharmacokinetic Parameters Prior to Analysis
The plasma PK parameters for PF-[ADDRESS_532908] PF-07321332 Area under the plasma 
concentration -time profile from 
time 0 to the time of C lastLinear/Log trapezoidal method.
AUC inf*PF-[ADDRESS_532909]+ (C last*/kel), Where C last*is 
the predicted plasma concentration 
at the last quantifiable time point 
estimated from the log -linear 
regression analysis .
Cmax PF-[ADDRESS_532910] occurrence.
C12 PF-07321332 Concentration at 12h Observed directly from data .
C24 PF-07321332 Concentration at 24h Observed directly from data .
t½*PF-07321332 Term inal elimination half -life Log e(2)/k el, where k elis the terminal 
phase rate constant calculated by a 
linear regression of the log -linear 
concentration -time curve. Only 
those data points judged to describe 
the terminal log -linear decline w ill 
be used in the regression.
CL/F*PF-07321332 Apparent clearance Calculated as AUC inf/Dose.
Vz/F*PF-07321332 Apparent volume of distribution Calculated as Dose/(AUC inf×kel).
*As data permit.
If urine samples need to be anal yzed (See Section 8. 4.2), the following urine PK parameters 
(Table 4) will be calculated for PF-07321332 ( as data permit ) :
Table 4. Urine PK Parameters
Param eter Analyte Definition Method of Determ ination
Ae48 PF-07321332 Total amount of unchanged drug 
excreted in the urine over 48 hoursSum of amount excreted for each 
collection period.
Ae48% PF-07321332 Total amount of unchanged drug 
excreted in the urine over 48 hours, 
expressed as percent of dose100×(Ae 48/Dose)
CL r PF-07321332 Renal clearance Ae48/AUC [ADDRESS_532911] unblinded reviews of the data during the course of the study  for the 
purpose of safet y assessment, facili tating PK/PD modeling, and/or support ingclinical 
development. 

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 629.5.Sample Size Determination
In Part 1, approximately  8 participants will be enrolled into the normal renal function group 
and approximately  8 participants into each of the mild and moderate renal impairment 
group s, to ensure approximately  6evaluable completers in each group. In Part 2, 
approximately  8participants will be enrolled to the severe renal groups to ensure 
approximately  6evaluable completers per group. Additional participants may  be enrolled 
into the normal renal function group to ensure adequate matching; however the total number 
will not exceed 12. The sample size is based on recommendations from the “FDA Guidance 
for Industry  -Pharmacokinetics in Patients with Impaired Renal Function -Study  Design, 
Data Anal ysis, and Impact on Dosing and Labeling”.6
Participants who discontinue from the stud y before completing all assessments may  be 
replaced at the discretion of the investigator and sponsor.

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 6310. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Reg ulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines ,including th e 
Declaration of Helsinki and CI OMS International Ethical Guidelines ;
Applicable ICH GCP guidelines;
Applicable laws and regulations , including applicable privacy  laws .
The protocol, protocol amendments, I CD, SRSD(s) , and other relevant documents 
(eg,advertisements) must be 
reviewed and approved by  [CONTACT_456] ,submitted to an I RB/EC 
by [CONTACT_093], and reviewed and approved by  [CONTACT_1201]/EC before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before implementati on of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
Protocols and an y substantial amendments to the protocol will require health authority  
approval prior to initiation except for chan ges necessary  to eliminate an immediate hazard to 
study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requiremen ts, policies, and procedures 
established by  [CONTACT_1201]/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
[CONTACT_1744]/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the I RB/EC, European regulation 
536/2014 for clinical studies (if applicable), European Medical Device Regulation 
2017/745 for clinical device research (if applicable), and all other applicable local 
regulations .
[IP_ADDRESS]. Reporting of Safety Is sues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that migh t influence the evaluation of the benefits and risks of the study  
intervention , [COMPANY_007] should be informed immediately .

PF-[ADDRESS_532912], and 
of an y serious breaches of this protocol or of the ICH GCP guidelines that the investigator 
becomes aware of.
10.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. Investigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study , including the 
risks and benefits, to the participant and answer all questions regarding the study .The 
participant should be given sufficient time and opportunity  to ask questions and to decide 
whether or not to participate in the trial.
Participants must be informed that their participation is voluntary. Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, privacy  and data protection requirements, where 
applicable, and the IRB/EC or stu dy center.
The investigator must ensure that each study  participant is fully  informed about the nature 
and objectives of the study, the sharing of data related to the study ,and possible risks 
associated with participation, including the risks associated w ith the processing of the 
participant ’s personal data. 
The participant must be informed that his/her personal study -related data will be used by  [CONTACT_20004]. The level of disclosure must also be 
explained to th
e participant.
The participant must be informed that his/her medical records may  be examined by  [CONTACT_160439], by  
[CONTACT_6667]/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that each study  participant is fully  informed about his or 
her right to access and correct his or her personal data and to withdraw consent for the 
processing of his or her personal data.
The medical record mu st include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the date on which 
the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the IC D.

PF-[ADDRESS_532913] current version of the IC D(s) during their 
participation in the study .
A cop y of the IC D(s) must be provided to the participan t.
Participants who are rescreened are required to sign a new IC D.
10.1.4. Data Protection
All partie s will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic form and 
will be password- protected to ensure that only authorized study  staff have access. The study  
site will implement appropriate technical and organizational measures to ensure that the 
personal data can be recovered in the event of disaster. In the event of a potential personal 
data breach, the stud y site will be responsible for determining whether a personal data breach 
has in fact occurred and, if so, providing breach notifications as required by [CONTACT_2371].
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. Any  
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will no t be transferred. All other identifiable data transferred to the 
sponsor will be identified by  [CONTACT_20007], participant-specific code. The study  site will 
maintain a confidential list of participant s who participated in the study, linking each 
participant ’s numerical code to his or her actual identity and medical record ID. In case of 
data transfer, the sponsor will protect the confidentiality  of participant s’ personal data 
consistent with the c linical study agreement and applicable privacy  laws.
10.1.5. Committees Structure
[IP_ADDRESS]. Data Monitoring Committee 
This study  will not use a DMC.
10.1.6. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with applicable local 
laws/regulations. In addition, [COMPANY_007] reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 66www.clinicaltrials.gov
[COMPANY_007] posts clinical trial results on www.clinicaltrials.gov for [COMPANY_007]- sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study  is conducted. These r esults are 
submitted for posting in accordance with the format and timelines set forth by  [CONTACT_20008].
EudraCT
[COMPANY_007] posts clinical trial r esults on EudraCT for [COMPANY_007] -sponsored interventional studies in 
accordance with the format and timelines set forth by  [CONTACT_422113].
www.pfizer.com
[COMPANY_007] posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 
[COMPANY_007] -sponsored interventional studies at the same time t he corresponding study  results are
posted to www.clinicaltrials.gov .
Documents within marketing authorization packages/submissions
[COMPANY_007] complies with the European Union Policy  0070, the proactive publication of clinical 
data to the EMA website. Clinical data, under Phase 1 of this policy ,includes clinical 
overviews, clinical summaries, C SRs, and appendices containing the protocol and protocol 
amendments, sample CRF s, 
and statistical methods. Clinical data, under Phase 2 of this 
policy ,includes the publi shing of individual participant data. Policy  0070 applies to new 
marketing authorization applications submitted via the centrali zed procedure since 
01January 2015 and applications for line extensions and for new indications submitted via 
the centralized p rocedure since 
01July 2015.
Data sharing
[COMPANY_007] provides researchers secure access to patient- level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute sto the scientific understanding of the 
disease, target, or compound class. [COMPANY_007] will make data from these trials available 
24months after study  completion. Patient- level data will be anon ymized in accordance with 
applicable privacy  laws and regulations. CSRs will have personally  identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analyses. Research teams must include a biostatistician. Data will not 
be provi ded to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 6710.1.7. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  [CONTACT_20010].
Guidance on completion of CRFs wil l be provided in the CRF Completion Requirements 
document.
The investigator must ensure that the CRFs are securel y stored at the study site in encrypted 
electronic form and are password -protected to prevent access by  [CONTACT_20011].
The investi gator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents. This 
verification may  also occur after study  completion. I t is important that the investigator(s) and 
their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy , including definition of study  critical data items and 
processe s(eg, risk- based initiatives in operations and quality ,such as risk management and 
mitigation strategies and analytical risk-based monitoring), methods, responsibilities ,and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual , or on- site monitoring) , are provided in the data management plan and 
monitoring plan maintained and utilized by  [CONTACT_36613].
The sponsor or designee is responsible for the data management of this study ,including 
quality  checking of the data.
Records and documents, including signed IC Ds, pertaining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the sponsor. No records may  be 
transferred to another location or part y without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securel y for aslong as they  are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_78245] y deleted from all systems.
The investigator(s) will notify  the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study . Furthermore, the investigator will cooperate 
with the 
sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly  resolve any  discrepancies that a re identified 
between the stud y data and the participant's medical records. The investigator will promptly  
provide copi[INVESTIGATOR_19946]. Before response 

PF-[ADDRESS_532914] maintain accurate documentation (source data) that supports the 
information entered in the CRF.
Study  mon itors will perform ongoing source data verification to confirm that data entered 
into the CRF by  [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and tha t the study  is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP guidelines, and all applicable regulatory  requirements.
10.1.9. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study  
start date.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to the sponsor 
or designee/ CRO if requested to do so by  [CONTACT_51025] I RB/EC or if such termination is 
required to protect the health of study  participants .

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 69Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or the ICH GCP 
guidelines ;
Inadequate recruitment of participants by  [CONTACT_093];
Discontinuation of further study  intervention development .
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the r egulatory  authorities, and any  CRO(s) used in the study  of 
the reason for termination or suspension, as specified by  [CONTACT_20013]. The investigator shall promptly  inform the participant and should assure 
appropriate participant th erapy and/or follow -up.
Study  termination is also provided for in the clinical study  agreement. If there is any  conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.10. Publication Policy
The results of this stud y may be published or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 1year after the end of the stud y 
(or study  termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any  subsequent publications ,
such as secondary
 manuscripts, and submit s all manuscripts or abstracts to the sponsor 
30days before submission. This allows the sponsor to protect proprietary  information and to 
provide comments , and the investigator will, on request, remove an y previously undisclosed 
confidential information before disclosure, except for an y stud y-or [COMPANY_007] -intervention 
related information necessary  for the appropriate scientific presentation or understanding of
the study  results.
For all publications relating to the stud y, the investigator will compl y with recognized ethical 
standards concerning publications and authorship, including those established by  [CONTACT_19483].
The sponsor will comply  with the requirements for publication of the over all study  results 
covering all i nvestigator sites. In accordance with standard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their 
entirety and not as 
individual site data. In this case, a coordinating investigator [INVESTIGATOR_78246].
Authorship of publications for the overall study  results will be determined by  [CONTACT_78275] I nternational Commi ttee of Medical Journal Editors authorship 
requirements. 

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 70If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.
10.1.11. Sponsor’s Qualified Medical Personnel
The contact [CONTACT_1133]'s appropriately  qualified medical personnel for the 
study  is documented in the study  contact [CONTACT_216482].
To facilitate access to appropriatel y qualified medical personnel for study -related medical 
questions or problems, partic ipants are provided with an ECC at the time of informed 
consent. The ECC contains, at a minimum, (a) protocol and study  intervention identifiers, (b) 
participant’s stud y identification number, (c) site emergency phone number active 
24hours/day , 7days per week, and (d) [COMPANY_007] Call C enter number.
The ECC is intended to augment, not replace, the established communication pathway s 
between the investigator, site staff, and study  team. The ECC is to be used by  [CONTACT_422114] y only , as a means of reaching the investigator 
or site staff related to the care of a participant. The [COMPANY_007] Call Center number should only  be 
used when the investigator and site staff cannot be reached. The [COMPANY_007] Call Center number is 
not intended for use b y the participant directly ; if a participant calls that number directl y, he 
or she will be directed back to the investigator site.

PF-07321332
Protocol C4671011Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 7110.2. Appendix 2: Clinical Laboratory Tests
The following safety laboratory tests will be performed at times defined in the SoA section of 
this protocol. Additional laboratory results may be reported on these samples as a result of the method of analysis or the type of analyzer used by [CONTACT_20019], or as derived from calculated values. These additional tests would not require additional collection of blood. Unscheduled clinical laboratory measurements may be obtained at any time during the study to assess any perceived safety issues.
Table 5. Protocol-Required Safety Laboratory Assessments
Hematology Chemistry Urinalysis Other
Hemoglobin
HematocritRBC count
MCV
MCHMCHCPlatelet countWBC count
Total neutrophils 
(Abs)Eosinophils (Abs)Monocytes (Abs)Basophils (Abs)Lymphocytes (Abs)BUN/urea and creatinine
a
Glucose (fasting)
Calcium
Sodium
PotassiumChlorideTotal CO
2(bicarbonate)
AST, ALT
Total bilirubin
Alkaline phosphataseUric acidAlbuminTotal proteinCreatine kinase
TSH and free T4Local Dipstick:
pH
Glucose (qual)
Protein (qual)
Blood (qual)KetonesNitritesLeukocyte esterase
Urobilinogen
Urine bilirubin
Laboratory:
Microscopyb•SARS-CoV-2 RT-PCR
•aPTT
•PT-INR
•Fibrinogen
•FSHc
•Urine drug screeningd
•Breath or urine alcohol 
teste
•Pregnancy test ( β-hCG)f
•HIV
•HbsAg
•HbcAb
•HCVAb 
•Urine myoglobing
a. Only serum creatinine will be assessed at S2 for eGFR assessment.
b. Only if urine dipstick is positive for blood, protein, nitrites, or leukocyte esterase.c. At S1 for confirmation of postmenopausal status only.d. At S1 and Day -1; The minimum requirement for drug screening includes cocaine, THC, 
opi[INVESTIGATOR_858]/opi[INVESTIGATOR_2438], benzodiazepi[INVESTIGATOR_1651], and amphetamines (others are site and study specific).
e. Complete at S1 and Day -1.
f. Local urine testing will be standard for the protocol unless serum testing is required by [CONTACT_216483]/EC. Serum or urine β-hCG for female participants of childbearing potential.
g. Reflex testing for creatine kinase >10 × ULN.
The investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the CRF.
Any remaining serum/plasma from samples collected for clinical safety laboratory 
measurements at baseline and at all times after dose administration may be retained and stored for the duration of the study.
 
These data will not be included in the CSR. Samples to be used for this 
purpose will be shipped to either a [COMPANY_007]-approved BBS facility or other designated laboratory and retained for up to 1 year following the completion of the study.CCI
PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 7210.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study 
participant, temporally associated with the use of study intervention, whether or 
not considered related to the study  intervention.
Note: An AE can therefore be an y unfavorable and uni ntended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) 
temporally associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or 
urinaly sis) or other safety  assessments (eg, ECG, radiological scans, vital sign 
measurements), including those that worsen from baseline, considered clinically  
significant in the medical and scientific judgment of the investigator. Any 
abnor mal laboratory  test results that meet any  of the conditions below must be 
recorded as an AE:
Is associated with accompany ing s ymptoms;
Requires additional diagnostic testing or medical/surgical intervention ;
Leads to a change in study  dosing (outside of any protocol -specified dose 
adjustments) or discontinuation from the study , significant additional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition, including either 
an increase in frequency  and/or intensity  of the condition.
New condition detected or diagnosed after stud y intervention administration ,
even though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE or SAE unless it is an intentional overdose taken with possible 
suicidal/self- harming intent. Such overdoses should be reported regardless of 
sequelae.

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 73Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments that are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms 
of the disease/disorder being stu died, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (soci al and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) 
present or detected at the start of the study  that do not worsen.
10.3.2. Definition of an SAE
AnSAE is defined as any untoward medical occurrence that, at any dose, meets one 
or more of the criteria listed below:
a.Results in death
b.Is life -threatening
The term “life-threatening ”in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event that hypotheticall y might have caused death if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_216472], hospi[INVESTIGATOR_12994] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_23917]/or treatment that would not have been appropriate in the phy sician’s 
office or outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. 
If a complication prolongs hospi[INVESTIGATOR_23919], the 
event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or w as 
necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen 
from baseline is not considered an AE.

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 74d.Results in persistent or significant disability/incapacity
The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance ,
such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle), thatmay interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Is a suspected transmission via a [COMPANY_007] product of an infectious agent, 
pathogenic or non -pathogenic, is considered serious.
The event may  be suspected from clinical s ymptoms or laboratory  findings 
indicating an infection in a participant exposed to a Pf izer product. The terms 
“suspected transmission” and “transmission” are considered s ynon ymous. These 
cases are considered unexpected and handled as serious expedited cases b y 
pharmacovigilance personnel. Such cases are also considered for reporting as 
product defects, if appropriate.
g.Other situations:
Medical or scientific judgment should be exercised by [CONTACT_216484] ,such as 
significant medical events that may  jeopardize the participant or may  require 
medical or surgical intervention to prevent one of the other outcomes listed in the 
above definition. These events should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or development of 
drug dependency  or drug abuse.
10.3.3. Recording/Reporting and Follow -Up of AE sand/or SAE sDuring the Active 
Collection Period
AE and SAE Recording /Reporting
The table below summarizes the requirements for recording AEs on the CRF and for 
reporting SAEs on the CT SAE Report Form to [COMPANY_007] Safet ythroughout the active 
collection period . These requirements are delineated for 3 ty pes of events: (1) SAEs; (2) 
nonserious AEs; and (3) exposure to the study  intervention under stud y during 
pregnancy  or breastfeeding, and occupational exposure. 

PF-[ADDRESS_532915] SAE 
Report Form to [COMPANY_007] 
Safety Within 24 Hours 
of Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeedingAll AEs/SAEs associated 
with exposure during 
pregnancy  or breastfeeding
Note: Instances of EDP or 
EDB not associated with an 
AE or SAE are not captured 
in the CRF.All instances of EDP are 
reported (whether o r not 
there is an associated 
SAE)*
All instances of EDB are 
reported (whether or not 
there is an associated 
SAE).**
Environmental or 
occupational exposure 
to the product under 
study  to a non -
participant (not 
involving EDP or EDB).None. Exposure to a study  
non-participant is not 
collected on the CRF.The exposure (whether or 
not there is an associated 
AE or SAE) must be 
reported.***
* EDP (with or without an associated AE or SAE): any  pregnancy  information 
is reported to [COMPANY_007] Safety using CT SAE Report Form and EDP 
Supplemental Form; if the EDP is associated with an SAE, then the SAE is 
reported to [COMPANY_007] Safet y using the CT SAE Report F orm. 
** EDB is reported to [COMPANY_007] Safety using the CT SAE Report Form which 
would also include details of an y SAE that might be associated with the 
EDB. 
*** Environmental or Occupational exposure : AEs or SAEs associated with 
occupational exposure are re ported to [COMPANY_007] Safety  using the CT SAE 
Report Form.

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 76When an AE or SAE occurs, it is the responsibility  of the investigator to review 
all documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE or SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety  in lieu of completion of the CT SAE Report 
Form /AEor SAE CRF p age.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_007] Safety .In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_216473] .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis 
(not the individual signs/sy mptoms) will be documented as the AEor SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: Asymptomatic or mild sy mptoms; clinical or diagnostic observations only ; 
intervention not indicated.
Moderate: Minimal, local or noninvasive intervention indicated; limiting age -
appropriate instrumental ADL. Instrumental ADL refers to preparing meals, 
shoppi[INVESTIGATOR_3112], using the telephone, ma naging money , etc.
Severe: Severe or medically  significant but not immediately  life-threatening; 
hospi[INVESTIGATOR_3111]; disabling, limiting 
self care ADL. Self care ADL refers to bathing, dressing and undressing, feed ing 
self, using the toilet, taking medications, and not bedridden.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 77If required on the AE page of the CRF, the investigator will use the adjectives 
MILD, MODERATE, SEVERE, or VERY SEVERE to describe the maximum 
intensity  of the AE. The severit y of the AE should be determined using the Toxicity  
Grading Scale: 
MILD Does not interfere with participant 's usual function.
MODERATE Interferes to some extent with participant 's usual function.
SEVERE Interferes significantl y with participant 's usual function.
VERY SEVERE Unacceptable and intolerable events or events which are 
irreversible or cause the participant to be in imminent danger of 
death.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE or SAE. The investigator will use clinical 
judgment to determine the relationship.
A “reasonable possibility” of a relationship conveys that there are facts, 
evidence, and/or arguments to suggest a causal relationship, rather than a 
relationship cannot be ruled out.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration, will be considered and investigated.
The investigator will also consult the IB and/or product information, for 
marketed produc ts, in his/her assessment.
For each AE or SAE, the investigator must document in the medical notes that 
he/she has reviewed the AE or SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the 
sponsor .

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 78The investi gator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send a nSAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the 
event, then the event will be handled as “related to study  intervention ” for 
reporting purposes, as defined by  [CONTACT_456] . In addition, if the investigator 
determines that an SAE is associated with study  procedures, the investigator 
must record this causal relationship in the source documents and CRF, and report 
such an assessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE reporting re quirements.
Follow -Up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of 
supplemental measurements and/or evaluations, as medically  indicated or as 
requested b y the sponsor ,to elucidate the nature and/or causalit y of the AE or 
SAE as fully  as possible. This may  include additional laboratory  tests or 
investigations, histopathological examinations, or consultation with other 
healthcare providers .
If a participant dies during p articipation in the study  or during a recognized 
follow -up period, the investigator will provide [COMPANY_007] Safet y with a cop y of any 
postmortem findings, including histopathology .
New or updated information will be recorded in the originally  submitted 
documen
ts.
The investigator will submit any  updated SAE data to the sponsor within 
24 hours of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety will be the 
electronic data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool ( see next section) to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as the data
become available.

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 79After the stud y is completed at a given site, the electronic data collection tool 
will be taken off -line to prevent the entry  of new data or changes to existi ng data.
If a site receives a report of a new SAE from a study  participant or receives 
updated data on a previously  reported SAE after the electronic data collection 
tool has been taken off -line, then the site can report this information on a paper 
SAE for m (see next section) or to [COMPANY_007] Safet y by [CONTACT_756].
SAE Reporting to [COMPANY_007] Safety via CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to [COMPANY_007] Safety .
In circumstances when the facsimile is not working , notification by  [CONTACT_20021] a cop y of the CT SAE Report Form sent by  [CONTACT_20022].
Initial notification via telephone does not replace the need for the investigator to 
complete and si gn the CT SAE Report Form pages within the designated 
reporting time frames.

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 8010.4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the intervention period and for at least 28daysafter the last dose of stud y intervention, which
corresponds to the time needed to eliminate reproductive safe ty risk of the study  
intervention(s) :
Refrain from donating sperm.
PLUS either :
Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and usual lifesty le (abstinent on a long -term and persistent basis) and 
agree to remain abstinent .
OR
Must agree to use contraception/barrier as detailed below:
Agree to use a male condom and should also be advised of the benefit for a 
female partner to use a highl y effective method of contraception as a condom may 
break or l eak when having sexual intercourse with a woman of childbearing 
potential who is not currently  pregnant.
In addition to male condom use, a highl y effective method of contraception may be 
considered in WOCBP partners of male participants (refer to the list of highly  
effective methods below in Section 10.4.4).
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least 
1of the following conditions applies:
Is not a WOCBP (see definitions below inSection 10.4.3).
OR
Is a WOCBP and using a contraceptive method that is highly
 effective (with a failure 
rate of <1% per year), preferably with low user dependency , as described bel ow
during the intervention period and for at least [ADDRESS_532916] dose of study  
intervention ,which corresponds to the time needed to eliminate any  reproductive 
safet y risk of the study  intervention(s) .The investigator should evaluate the 
effectiv eness of the contraceptive method in relationship to the first dose of study  
intervention.

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 81The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an early undetected 
pregnancy . 
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenopausal female with 1 of the following:
Documented h ysterectom y;
Documented bilateral salpi[INVESTIGATOR_1656] ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion 
should be applied to determining study  entry .
Note: Documentation for any  of the above categories can come from the site 
personnel’s review of the participant’s medical records, medical examination, or 
medical history  interview. The method of documentation should be recorded in the 
participant’s medical record for the stud y.
2.Postmenopausal female .
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. In addition :
A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years old and not using hormonal 
contraception or HRT. 
A female on HRT and whose menopausal status is in doubt will be required to 
use one of the nonestrogen hormonal highl y effective contraception methods 
if they  wish to continue their HRT during the study .Otherwise, they  must 
discontinue HRT to allow confirmation of postmenopausal status before study  
enrollment.

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 8210.4.4. Contracepti onMethods
Contraceptive use b y men or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
Highly Effective Methods That Have Low User Dependen cy
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation .
2.Intrauterine device .
3.Intrauterine hormone -releasing s ystem.
4.Bilateral tubal occlusion (eg, bilateral tubal ligation)
.
5.Vasectomized partner .
A vasectomized partner is a highl y effective contraceptive method provided that 
the partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed. If not, an additional highl y effective method of contraception 
should be used. The spermatogenesis cy cle is approximately  90days.
Highly Effective Methods That Are User Dependent
6.Combined (estrogen- and progestogen -containing) hormonal contraception 
associated with inhibition of ovulation.
Oral;
Intravaginal;
Transdermal ;
Injectable .
7.Progestogen --only hormone contraception associated with inhibition of ovulation.
Oral;
Injectable .
8.Sexual abstinence .
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention. The reliability  of sexual abstinence needs to be 

PF-[ADDRESS_532917] be used in addition to the highl y 
effective methods listed above that are user dependent:
Male or female condom with or without spermicide;
Cervical cap, diaphragm, or sponge with spermicide;
A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods) .

PF-07321332
Protocol C4671011Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 84 
 
 
 
 
 
 
 
 
 CCI
PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 8510.6. Appendix 6: Liver Safety: Suggested Actions and Follow-U p Assessments
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tole rators,” while those who show transient liver injury  but adapt 
are termed “adaptors.” In some participant s, transaminase elevations are a harbinger of a 
more serious potential outcome. These participant s fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury , commonl y referred to as DILI.
Participant s who experience a transaminase elevation above 3 ×ULN should be monitored 
more frequently  to determine if they  are “adaptor s” or are “susceptible.”
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elevations 
(>2×ULN) b y several day s or weeks. The increase in TBili ty pi[INVESTIGATOR_216474]/ALT 
is/are still elevated above 3 ×ULN (ie, AST/ALT and TBili values will be elevated within 
the same lab orator y sample). In rare instances, by [CONTACT_22858], 
AST/AL T values might have decreased. This occurrence is still regarded as a potential DILI.
Therefore, abnormal elevations in either AST OR AL T in addition to TBili that meet the 
criteria outlined below are considered potential DILI (assessed per Hy ’s law criteria) cases
and should alway s be considered important medical events, even before all other possible 
causes of liver injury  have been excluded.
The threshold of laboratory  abnorma lities for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing conditions. Participant s who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to defin itively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participant s with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased f rom 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).

PF-[ADDRESS_532918]/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor. 
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_532919] and AL T and TBili for suspected Hy ’s law 
cases , additional laboratory  tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT/INR, total bile acids, and alkaline phosphatase. Consideration should also be given 
to drawing a 
separate tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for further contemporaneous analy ses at the time of the recognized initial 
abnormalities to determine etiology . A detailed history , including relevant inform ation, such 
as review of ethanol, acetaminophen /paracetamol (either by  [CONTACT_20025] a coformulated 
product in prescription or over -the-counter medications) , recreational drug, or supplement 
(herbal) use and consumption, family  history , sexual history , trav el history, history  of contact 
[CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis A, B, C, D, and E infection ,liver imaging (eg, biliary  tract) ,and collection of serum 
sample s for acetaminophen/paracetamol drug and/or protein adduct levels may be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevati on defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 8710.7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings T hat May Q ualify as AEs
Marked sinus bradycardia (rate <40 bpm) lasting minutes.
New PR interval prolongation >280 ms ec.
New prolongation of QTcF to >480 ms ec(absolute) or by≥60msecfrom 
baseline .
New -onset atrial flutter or fibrillation, with controlled ventricular response rate: ie, 
rate<120 bpm .
New -
onset typeI second - degree (Wenckebach) AV block of >30 seconds’
duration.
Frequent PVCs, triplets , orshort intervals (<30 seconds) of consecutive 
ventricular complexes .
ECG Findings T hat May Q ualify as SAEs
QTcF prolongation >500 ms ec.
New ST- T changes suggestive of my ocardial ischemia .
New -onset l eft bundle branch block (QRS >120 ms ec).
New -onset right bundle b ranch block (QRS >120 msec).
Symptomatic bradycardia .
Asystole:
In awake, s ymptom -free participant s in sinus rhy thm, with documented 
periods of as ystole ≥3.0 seconds or an y escape rate <40 bpm, or with an 
escape rh ythm that is below the AV node. 
In awake, s ymptom -free participant s with atrial fibrillation and brad ycardia 
with [ADDRESS_532920] 5 seconds or longer. 
Atrial f lutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained s upraventricular tachycardia (rate >120 bpm) (“sustained ”= short 
duration with relevant symptoms or lasting >1 minute) .

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 88Ventricular r hythms >30 seconds’ duration, including idioventricular rhy thm 
(heart rate <40 bpm), accelerated idioventricular rhy thm ( HR > 40bpm to
<100 bpm), and monomor phic/poly morphic ventricular tach ycardia (HR 
>100 bpm (such as torsades de pointes) ).
Type IIsecond -degree (Mobitz II)AVblock.
Complete (third
-degree) heart block.
ECG Findings T hat Q ualify as SAEs
Change in pattern suggestive of new m yocardial infarction .
Sustained ventricular t achy arrhy thmias (>30 seconds ’duration) .
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requ iring 
cardioversion .
Ventricular fibrillation/ flutter .
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experience .
The enumerated list of major events of potential clinical concern are recommended as “alerts ”or 
notifications from the core ECG lab oratory to the investigator and [COMPANY_007] study team ,and not to be 
considered as all inclusive of what to be reported as AEs/SAEs.

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 8910.8. Appendix 8: Prohibited and Precautionary Concomitant Medications That May 
Result in DDI
The prohibited concomitant medications listed below should not be taken with PF-[ADDRESS_532921] of drugs prohibited or precautionary  for potential DDI concerns with the I MP may  
be revised during the course of the stud y with written notification from sponsor, to include or 
exclude specific drugs or drug categories for various r easons ( eg,emerging DDI results for 
the IMP, availability  of new information in literature on the DDI potential of other drugs).
This is not an all -inclusive list. Site staff should consult with the sponsor or designee with 
any questions regarding potent ial DDI.
Prohibited Medications
Medications that are Strong Inducers of CYP3A4a
Drug Class Specific Medication Clinical Comments
Anti -infectives Rifampin Potential to impact the PK of 
PF-[ADDRESS_532922]. John's wort
Medications Dependent on CYP3A4 for Clearance, with Drug Interactions with
PF-07321332/ritonavira
Alpha 1 -Adrenoreceptor 
AntagonistAlfuzosin Risk of hypotension, syncope
Antianginal Ranolazine Risk of cardiac arrhythmias 
Antiarrhythmics Amiodarone, Bepridil, Flecainide, 
Propafenone, Quinidine, 
Dronedarone, EncainideRisk of cardiac arrhythmias 
Anti -gout Colchicine Potential for serious and/or life -
threatening reactions in patients with 
renal and/or hepatic impairment
Antihistamines Astemizole, Terfenadine Risk of cardiac arrhythmias
Antipsychotics Lurasidone Potential for serious and/or life -
threatening reactions
Ergot Derivatives Dihydroergotamine, Ergonovine, 
Ergotamine, MethylergonovineRisk of acute ergot toxicity 
(peripheral vasospasm and ischemia 
of the extremities)
HMG CoA Reductase 
Inhibitors Lovastatin, Simvastatin Risk of rhabdomyolysis; consider 
alternative agent : pravastatin
Neuroleptic Pi[INVESTIGATOR_422092] -5 inhibitors Sildenafil (Revatio) -PAH Risk of visual disturbances, 
hypotension, prolonged erection, and 
syncope
Sedatives/hypnotics Oral Midazolam, Triazolam Risk of prolonged sedation or 
respi[INVESTIGATOR_2341]
a.If a drug is not listed, it should not automatically be assumed it is safe to co -administer .

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 90Precautionary Medications
Medications to be Used with Caution when Co -administered with PF-07321332/ritonavi ra
Drug Class Specific Drugs Clinical Comments 
Anesthetic Meperidine Dosage increase and long -term use of 
meperidine with ritonavir are not 
recommended due to the increased 
concentrations of the metabolite
norm eperidine which has both analgesic 
activity and CNS stimulant activity ( eg, 
seizures).
Antiarrhythmics Disopyramide, Lidocaine, Mexiletine Caution is warranted and therapeutic 
concentration monitoring is 
recommended for antiarrhythmics when
co-administered with ritonavir, if 
available.
Anticancer Agents Dasatinibm, Nilotinibm, Vincristine, 
VinblastinePotential increase in anticancer agent.
Anticonvulsants Lamotrigine, 
Valproate
Phenytoin
Divalproex
Carbamazepi[INVESTIGATOR_422093]-administration may decrease 
lamotrigine, valproate, divalproex, and 
phenytoin concentrations. 
Co-administration may increase 
carbamazepi[INVESTIGATOR_53539] .Careful 
monitoring of adverse effects.
Alternative agents: Gabapentin 
Topi[INVESTIGATOR_422094]; consider 
alternative anticoagulant .
Co-administration may increase or 
decrease w arfarin levels. Frequent 
monitoring of INR during 
co-administration is recommended
Antidepressant Trazadone, Desipramine, Fluoxetine 
Paroxetine, Sertraline, Nefazadone, 
Amitriptyline, Nortriptyline
Bupropi[INVESTIGATOR_422095] .
Co-administration may decrease 
bupropi[INVESTIGATOR_422096]. 
Antiemetic Dronabi nol Co-administration may increase 
dronabinol concentrations; a dose 
reduction of dronabinol may be needed.
Anti -infective Clarithromycin Co-administration may increase 
clarithromycin concentration. 
Antifungals Itraconazole , Ketoconoazole
VoriconazoleCo-administration may increase 
itraconazole, ketoconazole
concentration. Monitor for adverse 
effects.
Co-administration may decrease 
voriconazole concentration .

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 91Precautionary Medications
Medications to be Used with Caution when Co -administered with PF-07321332/ritonavi ra
Antimycobacterial Bedaquiline, Rifabutin Co-administration may increase 
bedaquiline, rifabutin concentrations.
Antiparasitic Atovaquone
QuinineCo-administration may decrease 
atovaquone concentrations.
Co-administration may increase quinine
Antipsychotic Perphenazine, Risperidone, 
Thioridazine, Quetiapi[INVESTIGATOR_422093]-administration may increase 
antipsychotic concentrations. 
Beta Blockers Metoprolol, Timolol Co-administration may increase beta-
blocker concentration. A dose decrease 
may be needed for these drugs when 
co-administered with ritonavir.
Bronchodilator Theophylline Increased dose of theophylline may be 
required. 
Calcium Channel 
Blockers Diltiazem, Verapamil, Felodipi[INVESTIGATOR_050], 
Nicardipi[INVESTIGATOR_050], Nisoldipi[INVESTIGATOR_050] , Nifedipi[INVESTIGATOR_050], 
Amlodipi[INVESTIGATOR_422093]-administration may increase 
concentrations. The impact on the PR 
interval of co -administration of ritonavir 
with other drugs that prolong the PR 
interval (including calcium channel 
blockers) has not been evaluated. If 
co-administration is indicated, consider a 
dose reduction (amlodipi[INVESTIGATOR_422097] 50%). 
Close monitoring is recommended .
Cardiac Glycosides Digoxin Co-administration increases digoxin 
concentration .
Contraceptives Hormonal contraception Recommend barrier method
Endothelin Receptor 
AntagonistBosent an Co-administration may increase 
bosentan concentrations.
Hepatitis C direct 
acting antiviralsBoceprevir, Glecaprevir/Pi[INVESTIGATOR_422098], 
Sofosbuvir/Velpatasvir/Voxilaprevir
Ombitasvir/Paritaprevir/ Ritonavir , 
DasabuvirCo-administration is not recommended 
as it resulted in increased plasma 
concentrations of Hep C antiviral; 
Caution or not recommended .
HIV Protease 
Inhibitors
NNRTs, Fusion 
InhibitorsLopi[INVESTIGATOR_054], Amprenavir, Indinavir, 
Nelfinavir, Saquinavir , Atazanavir,
Abacavir, Didanosine ,Darunavir, 
Tipranavir, ZidovudineCo-administration may increase HIV 
protease inhibitor concentrations; 
co-administer with caution .
HIV- 1 CCR5 
antagonistMaraviroc See prescribing information for 
maraviroc for details on 
co-administration of maraviroc and 
ritonavir -containing proteases inhibitors.
HMG CoA reductase 
inhibitorsAtorvastatin, Rosuvastatin Use with caution; risk of myopathy 
including rhabdomyolysis .Use low est 
dose of statin .
Alternative agents: Pravastatin .
Hypoglycemics Glipi[INVESTIGATOR_7130], Tolbutamide
RepaglinidePotentially decrease glipi[INVESTIGATOR_422099]. 
Potentially increase repaglinide 
concentrations. 

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 92Precautionary Medications
Medications to be Used with Caution when Co -administered with PF-07321332/ritonavi ra
Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus Co-administration may increase 
immunosuppres sant concentrations. 
Integrase Inhibitor Raltegravir The effects of ritonavir on raltegravir 
with ritonavir dosage regimens greater 
than [ADDRESS_532923] been observed .
Fentanyl concentration may increase.
Analgesic concentrations may increase 
and a dose decrease may be needed for 
these drugs when co -administered.
PDE -5 Inhibitors Avanafil, Sildenafil, Tadalafil, 
VardenafilIncreased concen trations of PDE -5 
inhibitors .
Sedative/Hypnotic Buspi[INVESTIGATOR_5331], Clorazepate, Diazepam, 
Estazolam, Flurazepam, Zolpi[INVESTIGATOR_6730], 
MidazolamIncreased concen trations of 
sedative/hypnotic.
Steroids Budesonide, Dexamethasone, 
Prednisone, Fluticasone, Budenoside, Increased concentration of steroid. 
Stimulant Methamphetamine Increased methamphetamine 
concentrations. Use with caution. 
a.If a drug is not listed, it should not automatically be assumed it is safe to co -administer .

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 9310.9. Appendix 9: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
 ongoing/continuous event
3CLpro3C-like protein
Ab antibody
Abs absolute
ADL activities of daily  living
Ae amount of unchanged drug excreted in urine
Ae48 total amount of unchanged drug excreted in the urine over 
48hours
Ae48% total amount of unchanged drug excreted in the urine over 
48hours, expressed as percent of dose
AE adverse event
ALT alanine aminotransferase
ANOVA analysis of variance
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
AUC area under the concentration -time curve
AUC inf area under the plasma concentration -time curve from time [ADDRESS_532924] dose 
CCR5 C-C chemokine receptor ty pe 5
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD chronic kidney  disease
CKD -EPI [INVESTIGATOR_19957] -Epi[INVESTIGATOR_422100]-07321332
Protocol C4671011Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 94Abbreviation Term
CL total clearance of drug from eg, plasma
CL/F apparent clearance of drug from eg, plasma
Clast last observed (quantifiable) plasma concentration
CLr renal clearance of drug from eg plasma
Cmax maximum observed plasma concentration
CNS central nervous system
CO 2 carbon dioxide (bicarbonate)
COVID-[ADDRESS_532925]-in-human
fm fraction metabolized
FSH follicle stimulating hormone
fu fraction unbound
GCP Good Clinical Practice
GGT gamma-glutamyl transferase
GFR glomerular filtration rateCCI
PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 95Abbreviation Term
GLP Good Laboratory  Practice
h hour
HBcAb hepatitis B core antibod y
HBsAg hepatitis B surface antigen
HCoV -OC43 human coronavirus OC43
HCoV -229E human coronavirus 229E
HCoV -HKU1 human coronavirus HKU1
HCoV -NL63 human coronavirus NL63
HCVAb hepatitis C antibody
HCV hepatitis C virus
hep C hepatitis C
HIV human immunodeficiency virus
HMG CoA reductase 3-hydroxy -3-methy l-glutary l-CoA reductase
HR heart rate
HRT hormone replacement therap y
IB Investigator's Brochure
ICD informed consent document
ICH International Council for Harmonisation
ID identification
IMP investigational medicinal product
IND Investigational New Drug 
INR international normalized ratio
IP investigational product
IP manual investigational product manual
IPAL Investigational Product Accountability  Log
IRB Institutional Review Board
ISO International Organization for Standardization
IV intravenous
KDOQI Kidney  Disease Outcomes Quality  Initiative 
kel terminal phase rate constant calculated b y a linear regression of 
the log -linear concentration -time curve.
Ki inhibition constant
LFT liver function test
MAD multiple ascending dose
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MERS Middle East respi[INVESTIGATOR_422101]
N/A not applicable

PF-[ADDRESS_532926] level
PACL Protocol Administrative Change Letter
PAH pulmonary  arterial hy pertension
PCR polymerase chain reaction
PD pharmacod ynamic(s)
PDE -5 phosphodiesterase t ype 5
pH potential of hy drogen
PK pharmacokinetic(s)
PT prothrombin time
PT-INR prothrombin time-international normalized ratio
PVC premature ventricular contraction/complex
q12h every  [ADDRESS_532927]
QTc corrected QT interval
QTcF corrected QT (Fridericia method)
qual qualitative
RBC red blood cell
RNA ribonucleic acid
RT-PCR reverse -transcriptase poly merase chain reaction
S1 Screening Visit [ADDRESS_532928] upper limit of normal
US [LOCATION_002]
USPI [INVESTIGATOR_185578] I nformation
Vz/F apparent volume of distribution
WBC white blood cell
WHO World Health Organization
WOCBP woman/women of childbearing potential

PF-07321332
Protocol C4671011
Final Protocol Amendment 2, 08 July 2021 
PFIZER CONFIDENTIAL
Page 9811.REFERENCES
1WHO Situation Report 51. 11 March 2020. Available from: 
https://www.who.int/emergencies/diseases/novel- coronavirus- 2019/situation -reports. 
Accessed: 29 March 2020.
2Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CLpro) structure: 
basis for design of anti -SARS drugs. Science. 2003;300:1763 -7.
3Investigator’s Brochure, (PF- 07321332). June 2021.
4Ritonavir [package insert]. North Chicago, IL: [COMPANY_013] Inc; 2017. Available from: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209512lbl.pdf. Accessed: 
24 June 2021.
5Levey  AS, Coresh J, Balk E, et al. National Kidney  Foundation practice guidelines for 
chronic kidney  disease: evaluation, classification, and stratification. Annals of internal 
medicine. 2003;139(2):137-47.
6Guidance for industry : pharmacokinetics in patients with impaired renal function —study  
design, data anal ysis, and impact on dosing and labeling. US FDA. Available at: 
https://www.fda.gov/regulatory -inform ation/search -fda-guidance -
documents/pharmacokinetics -patients
-impaired -renal -function -study -design -data-
analysis-and-impact- dosing -and. Accessed: 03 May  2021.
